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Abstract 
 
 
The bovine papillomavirus type 1 E2 protein is a multifunctional early viral protein 
with roles in all phases of the cell cycle.  E2 is required during G1 as a 
transcription factor, in S phase to initiate viral replication and during mitosis to 
tether the viral genome to dividing DNA.  The viral genome contains 17 E2 
binding sites, the majority of which are concentrated in the long control region 
(LCR), a regulatory region that is upstream of the viral coding sequence.  The 
role of these binding sites has been explored in vitro using small plasmids and 
E1 and E2 proteins expressed in bacteria and insect cells.  In this study we 
attempt to examine the placement of E2 on its binding sites during all phases of 
the cell cycle and in the context of a stably replicating viral system.      
 
As part of the examination of the role of E2 during mitosis, we have also 
examined the role of the cohesin protein Scc1 in viral tethering.  Two groups 
have published disparate reports identifying the cellular protein that binds to the 
transactivation domain of E2 to stably maintain viral genomes during cell division.   
Our group has published that it is the DNA helicase ChlR1 that is required for 
viral tethering, while it has been reported that it is the bromodomain protein Brd4 
that is responsible.   In this study we contribute to a report that shows that the 
cellular protein Scc1 binds to the viral genome through a ChlR1 independent 
mechanism.  The cohesin protein binds to BPV-1 E2 at intermittent stages of the 
 vi 
cell cycle and may be a factor in viral genome tethering.  This interaction may 
also be important for regulating viral transcription.  
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The Role of Papillomavirus in Disease 
 
 Papillomavirus is a small non-enveloped double stranded DNA virus with a 
circular genome of around 7900 base pairs.  This tiny genome contains an 
average 10 open reading frames, two of which code for structural proteins, the 
remainder for nonstructural.  Papillomaviruses are species specific and infect 
both birds and mammals, with over 100 types identified that infect humans alone 
(31).  These types are classified by differences in the E6, E7 and L1 proteins with 
a sequence variation greater than 10% required for the classification of a new 
type (33).   As papillomaviruses are nonenveloped they are very stable and can 
exist in the environment for extended periods of time, retaining 30% infectivity 
seven days after desiccation from cell extracts (134).  Despite this stability, which 
lends to the possibility of infection from inanimate objects, the most common 
form of transmission is direct contact with an infected individual of the same 
species (134). 
 The most common result of exposure to papillomavirus is a benign 
cutaneous lesion, or wart, occurring at the site of infection.  A wart is the result of  
altered growth patterns in epithelial cells.  The production of viral proteins causes 
the epidermal layer to retain increased numbers of cells resulting in subsequent 
epithelial thickening (156).  Most cutaneous warts develop on the hands and feet 
and are eventually cleared by the immune system of the infected individual. 
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 Subsets of persons who become infected by papillomavirus are 
genetically pre-disposed to a condition called epidermodysplasia verruciformis 
(EV).  The genes responsible for this susceptibility have been identified as the 
EVER1 (TMC6) and EVER2 (TMC8) genes located on chromosome 17 (133).  
Little is known of the function of these genes or their role in EV.  Individuals with 
suppressed immune systems or immunological disorders may also be afflicted 
with EV.  Persons suffering from this disease are unable to clear papillomavirus 
infection and will develop flat lesions on many areas of the body.  These lesions 
will often progress to carcinoma, especially in areas of the skin exposed to 
sunlight, e.g., the head, neck, arms and hands.  The HPV types 5 and 8 are most 
commonly found among patients with EV associated cancers (reviewed (122)). 
 In addition to epidermal infection, HPV is also capable of establishing 
infection in mucosal tissue.  This encompasses both genital and non-genital 
areas.  Infection by these types of HPV may result in genital warts, which again 
are often cleared by the host immune system.  In some cases infection by these 
types will progress to cervical cancer.   These genital-mucosal strains of HPV are 
often loosely classified into either the high-risk or low-risk categories. Those 
termed high risk are those most often associated with cancers of the cervix and 
include, but are not limited to, types 16, 18, 31,33, 39, 45, 52, 58.  The two main 
types responsible for genital warts, type 6 and 11 are considered low risk and are 
rarely found associated with cervical carcinoma (reviewed (192)). 
 Those types of HPV most associated with cervical cancer, 16 and 18, are 
the same types most often associated with a proportion of oropharyngeal, anal, 
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vaginal, vulvar and penile cancers (49).  Current data estimates that the numbers 
of cases of HPV associated non-cervical cancers in the United Sates roughly 
equal the number of HPV associated cervical cancers and the number of men 
affected by these cancers is equivalent to the number of women (49).  Unlike 
cervical cancer, where HPV is the causative agent in nearly 100% of all cases, 
the correlation between HPV infection and noncervical cancer is not, with a range 
from 36 to 93% of these cancers being associated with HPV (49).  
 Worldwide, the incidence of cervical cancer is highest in those areas with 
inadequate health care and where the number of lifetime sexual partners is high. 
Developing countries account for greater than 80% of the worldwide incidence of 
cervical cancer (126).  In 2002 the worldwide estimate for cervical cancer 
diagnoses was 500,000 with the number of deaths numbering 275,000 (127).  
Screening programs with consistent follow-up in the developed world have led to 
a reduction in deaths from cervical cancer.  However, even in the United States 
there are disparities in both the incidence and mortality rates.  During the five 
year period from 1998-2003 there were 65,074 cases of invasive cervical 
carcinoma with 24,707 reported deaths from cervical cancer in the United States 
(175).  Black and Hispanic women suffered from a higher incidence of cervical 
cancer than did white women, with increased incidence in the southern part of 
the country as compared to the Northeast, Midwest and West (175).  The 
introduction of a vaccine to combat cervical cancer may lead to reduced rates 
among all populations.  The two approved HPV vaccines by Glaxo-Smith-Kline 
and Merck, have shown to have a 95% effective rate against HPV types 16 and 
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18 (27, 143), however the cost is roughly $360 for the three dose regimen (77).  
Neither vaccine has been shown to effectively lead to regression of established 
HPV lesions or infections (143).   In developing countries and areas of the United 
States where many are unable to afford adequate health care the vaccine may 
not yet be a viable option for preventing HPV related carcinomas.   The vaccine 
has not shown to be protective for those who have been previously exposed to 
the virus, nor is it effective in 100% of vaccinated individuals.  There has also 
been shown to be little or no cross-protection achieved with the current vaccines, 
and as these types account for only 70% of cervical cancer cases it is important 
to realize there will continue to be HPV disease resulting from non-vaccine 
strains of the virus, necessitating continued work in the field of papillomavirus 
research and discovery.    
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The Cell Cycle and DNA Replication 
 
The cell cycle figures prominently in the experiments undertaken in this 
study.  The papillomavirus E2 protein is a multifunctional viral protein that has a 
role in all phases of the cell cycle.  In G1, E2 acts as a transcriptional activator.  
E2 binds to viral DNA in a sequence-specific manner through the C terminal DNA 
binding domain of the protein (6).  The N terminus serves as a transcriptional 
activator by binding cellular transcription factors and initiating transcription of viral 
proteins.  E2 remains bound to the viral genome, through the DNA binding 
domain, during S phase and attracts the papillomavirus E1 protein to the viral 
origin to initiate replication of the viral genome.  In preparation for mitosis E2 is 
bound to the viral genome, and to host factors through its activation domain, and 
tethers the viral genome to  the host chromosomes to ensure faithful segregation 
of the replicated viral genomes (72, 90, 131).   
Eukaryotic cells undergo alternate periods of growth, replication and 
division in a precisely regulated manner.  The replication phase (S) is 
accompanied by two gap phases (G1 and G2) and a mitotic phase (M) where 
separation of the replicated DNA occurs (reviewed (167)).  Upon differentiation or 
senescence the cells exit this cycle and are said be in G0.  Following mitosis 
daughter cells are in G1.  Here the cells grow, needing to double in size prior to 
the initiation of the DNA replication phase.  Once in S phase, DNA replication 
initiates and will proceed only once per cell cycle.  From there, the cells move 
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into G2, where centromere duplication occurs.  DNA replication and repair must 
be fully complete before the cells can proceed from G2 to mitosis.  Now in M 
phase, the newly replicated chromosomes, called sister chromatids, line up along 
the spindles, attached by their kinetochores, and wait for additional checkpoints 
to be satisfied before division is completed.  Failure to line up correctly or attach 
to a spindle will activate another checkpoint, and mitosis will be delayed until this 
checkpoint is satisfied.  Cells that have successfully exited mitosis find 
themselves in G1, ready to begin again (See figure I-1).   The cell cycle is a very 
complex, tightly regulated system with many check points in place to keep the 
cell from exiting, re-replicating and dividing without all the chromosomes properly 
duplicated, aligned and attached. These stages of the cell cycle are irreversible 
and rely not on single proteins but on a complex network of transient signals that 
provide directionality to the cycling cell (120). 
 Master regulators of the cell cycle are the cyclins and cyclin dependent 
kinases.  Through phosphorylation these proteins regulate transcription and 
degradation to control DNA replication, entry into and exit from mitosis.  The cell 
cycle begins with activation of cyclins in cells in G1 (Figure I-1). Cells are 
normally induced to begin replication through activation by mitogenic signaling 
through the Ras complex (69).  This signaling activates cyclin D and cyclin E 
which upregulate Cdk4/6 and Cdk2 respectively (37, 79, 121). When cells are 
quiescent, these kinases are inhibited by members of the cyclin kinase inhibitors 
(CKI) family, which includes the proteins p27KIP1 and p21CIP1/WAF1 (39, 56, 62, 
182). Upregulation of these kinases leads to hyper-phosphorylation of the 
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retinoblastoma protein (pRb), early in G1 by cyclin D/Cdk4, and late in G1 by 
cyclin E/Cdk2 (32, 101, 108, 110) (Figure I.1).  This results in release of 
repression by the transcription factor E2F, and an increase in transcription of 
factors required for S phase.   These factors include elements directly required 
for replication such as Orc1, Cdc6, and DNA polymerase alpha (128, Ohtani, 
1996 #186, 184), as well as for maintaining levels of factors such as cyclin D and 
E to ensure progress through S phase.  Cyclin E is upregulated by pRb, as is 
cyclin A, both of which are required for transition through S phase (38).   Cyclin 
A/Cdk2 maintains phosphorylation of pRb throughout S (38). 
In addition to blocking the progression of S phase by inhibiting 
transcription of essential factors, pRb also blocks replication by binding to the 
pre-replication complex (pre-RC) (51).  Mammalian DNA replication requires the 
formation of the pre-RC factors on the origin to enable the initiation of replication.  
The origin recognition complex (ORC) is a 6 member structure that is a 
component of the pre-RC.  The protein CDT1 then binds to ORC and recruits the 
six member DNA helicase component of the replication complex, the 
minichromosome maintenance proteins (MCM).  MCM proteins 2-7 are loaded at 
the origin by the factor CDC-6 (76).   
An additional member of the MCM family is required for replication.  
MCM10 is loaded onto DNA at the origin and CDC45 is then also added to the 
complex.  This initiates unwinding of the DNA and allows replication protein A 
(RPA), a single stranded (SS) DNA binding protein, access, to stabilize the SS 
DNA (76).  CDC45 is required for elongation of DNA synthesis and its 
 9 
association is followed by the addition of PCNA, which is loaded with the aid of 
replication factor C, and DNA polymerases  and .  Cyclin A/Cdk2 remains 
associated with the replication fork, is required for elongation, and is known to 
phosphorylate PCNA, pol  and pol  
Once S phase has begun and the origins of replication have fired, the 
cyclin-CDK complexes function to inactivate the proteins required for initiation in 
order to prevent re-replication.  Cdc6 is phosporylated by cyclin A/Cdk2 during S 
phase resulting in transport of the initiation factor into the cytoplasm, in order to 
prevent re-replication (28).  Phosphorylation and activation of MCM is also 
controlled through cyclinA/Cdk2 (74).  Following initiation of replication MCM is 
removed from chromatin by the movement of the replication fork and is not able 
to bind again without the licensing factor Cdc6.  CDT1 is expressed only in G1 
and S, and its activity is inhibited by the protein geminin, which is expressed only 
in S and G2 and is degraded late in mitosis (93, 104).   Cyclin E is also degraded 
during S to prevent another round of replication (112). 
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Figure I.1. The Cell Cycle.   A representation of the mitotic cyclins and     
their roles in the cell cycle.  The phases of the cell cycle are shown in the 
center.  See text for additional information.    
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 Cells progressing through S phase are unable to re-initiate replication and 
enter G2.  As they do, cyclin E is degraded, downregulating E2F and 
transcription of factors required for S phase.  During late S phase cells begin to 
accumulate Cdc20.  At the onset of mitosis, phosphorylation of the anaphase 
promoting complex/cyclosome (APC/C) by cyclin B/cdc2 and polo-like kinase 
(PLK) activates the ubiquitination function of the APC/CCDC20, resulting in the 
degradation of both cyclin A and cyclin B in pro-metaphase/metaphase (52).  The 
cellular protein securin is also degraded by the APC/CCDC20 allowing for the 
action of the protein separase, which cleaves the Scc1 protein allowing for mitotic 
segregation of sister chromatids (59, 165).  The geminin protein is degraded here 
as well, releasing the Cdt1 protein and allowing for another round of replication 
licensing, as does the degradation of the PKI p21 (4, 104).   Upon degradation of 
cyclin A/Cdk2 the APC/CCDC20 complex is replaced by the APC/CCDH1 following 
mitosis.   This complex completes the degradation of cyclin B and promotes the 
repression of S phase by degrading factors that ubiquitinate p27kip1 and 
p21cip1/waf1 allowing them to delay progression into S phase until G1 is complete 
(Figure I.1) (80). 
 
In order to examine the assembly of factors at the viral origin, cell cycle 
check points can be chemically induced by the addition of excess thymidine.   
Thymidine is phosphorylated to dTTP, which blocks the reduction of CDP by 
ribonucleotide reductase leading to a decrease in dCTP (13, 41).  This decrease 
results in replication forks stalled at the initiation of replication and activates both 
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the ATM and ATR pathways of DNA repair response blocking the cells in the 
very early stages of S phase (14).   This checkpoint activation provides a useful 
tool for examining viral proteins locked at the origin of replication, and is used 
extensively in this thesis. 
 
Aneuploidy, the incorrect number of chromosomes in a cell, is commonly 
found in tumor cells and tumor cell lines.  Cells have a method to combat this, 
which is the mitotic checkpoint, or spindle assembly checkpoint (reviewed in 
(161)).  As cells approach prometaphase (shown above) mitotic spindles form 
and the paired sister chromatids align and attach to the mitotic spindles by their 
kinetochores.  If all the chromosomes fail to properly align or attach to a spindle, 
the cells fail to progress to anaphase.  If all is well and the checkpoint is not 
activated, the anaphase promoting complex/cyclosome (APC/C) will bind Cdc20, 
target Securin and Cyclin B for destruction and release separase to cleave Scc1, 
the member of the cohesin complex that binds the sister chromatids together (17, 
26, 29).  The cells will then proceed through anaphase to exit mitosis through 
telophase and return to G1.  In this study we use the chemical nocodazole to 
block formation of microtubules in prometaphase, thus inducing the mitotic 
checkpoint and allowing examination of viral protein interactions at the onset of 
mitosis.  In the final chapter we will also introduce interactions between the 
papillomavirus E2 protein and members of the cohesin family. 
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Papillomavirus Life Cycle 
 The infectious papillomavirus particle is a non-enveloped icosahedral 
capsid 60 nm in diameter.  Papillomavirus genetic information is encoded on an 8 
kb circular genome that can be divided into three regions.  The first is the non-
coding long control region (LCR) or upstream regulatory region (URR); the early 
region encodes genes E1, E2, E4, E5, E6, and E7; and the third region encodes 
the late major and minor capsid proteins, L1 and L2.   
 The initial papillomavirus infection is believed to occur in the epithelium 
through micro-abrasions, allowing for the establishment of the infection in the 
dividing layer of basal cells.  These cells initiate as stem cells, become transit 
amplifying cells which divide several more times, eventually withdrawing from the 
cell cycle in the basal layer and entering into a differentiation pattern (176).  
Infection of this cell type leads to establishment of the viral genome as a stably 
replicating extra-chromosomal element, or episome (88), believed to occur 
through a high output viral genome replication event.  Episomes then replicate at 
a low copy number along with the cellular genome during S phase of the cell 
cycle, and faithfully partition to daughter cells upon division.  The expression of 
viral proteins E1 and E2 is required for the initiation of viral replication and 
establishment and maintenance of infection in dividing basal cells (53).  As these 
cells differentiate the E7 protein maintains them in a replication competent state 
(20).  The virus then begins a program of vegetative genome production, coupled 
with expression of late viral proteins, and assembly of virions, and is shed as the 
differentiated cells move to the surface.  The mechanism for this switch in viral 
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replication from initiation of infection to maintenance of a stable copy number, 
then to high-output genome reproduction, is not yet fully understood.   
 The role of the viral proteins E1 and E2 in the viral life cycle will be 
covered in depth in later chapters.  The role of E6 and E7 will be discussed 
briefly here.  Papillomavirus encodes only 2 proteins known to be required for 
replication, those are the E1 and E2.  The majority of the factors required are 
cellular proteins.  In order for the virus to continue to replicate in differentiating 
cells it is important that these cells continue to express components of the DNA 
replication machinery.  Papillomavirus E6 and E7 proteins maintain the 
differentiating cells in cycle so that vegetative replication and virion production 
can occur (45).  The retinoblastoma protein (pRb) binds to a member of the E2F 
transcription family during G1 effectively blocking induction of proteins required 
for genomic replication and inhibiting entry into S phase.   Phosphorylation of Rb 
by cyclin dependent kinases releases E2F, allowing for cell cycle progression 
(reviewed (166)).  E7 binds hypophosphorylated pRb, interrupting this cycle of 
regulation and allowing for transcription of genes required for replication (116).   
BPV-1 E7 has been shown to bind pRb only weakly (116), however it does 
activate c-Myc, leading to activation of cyclin-A and cyclin-E related kinases as 
an alternate method to maintain cells in a replication competent state (42). 
 Human papillomavirus E7 protein has primarily been shown to be a viral 
oncogene required for immortalization and transformation by high risk 
papillomaviruses (130, 173).  This is primarily due to its interactions with pRb 
family members. The high risk papillomavirus E6 protein is also required for 
16 
 
transformation of host cells.  E7 alone can immortalize human keratinocytes, but 
the presence of E6 increases the frequency of these events (9, 60).  
Papillomavirus E6 plays a major role in the extension of the replication window 
for the virus.  E6 binds the proteins E6AP, an E2 ubiquitin ligase, and p53 and 
through the proteasome will degrade the p53 protein (139, 140).  The presence 
of p53 blocks progression to S phase and its degradation abrogates the G1/S 
checkpoint allowing the cell cycle to progress.  P53, however, functions to cause 
growth arrest or apoptosis in cells in response to stress, DNA damage or un-
programmed entry into the cell cycle (138, 180) and as such is considered to be 
a tumor suppressor.  Loss of this tumor suppressor function leads to the 
possibility of continued replication of mutated genomes, furthering the 
transformation process.  While expression of E6 and E7 alone can immortalize 
human keratinocytes, transformation requires significant passaging, during which 
time an additional transforming event is believed to occur (reviewed (43, 65)).  
Regulation of transcription of E6 and E7 requires the papillomavirus E2 protein.  
Disruption of this protein, through mutation or integration of the viral genome into 
host DNA, is often found in HPV transformed cells (75) and may help initiate the 
immortalized phenotype through over-expression of E6/E7, leading eventually to 
HPV related cancers. 
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The E2 Protein 
 The papillomavirus E2 protein is a product of viral early gene expression.  
The BPV-1 E2 open reading frame (ORF) codes for a transactivation competent 
form of E2 (E2 or E2TA) which has a molecular mass of about 48 kDa, and two 
repressor forms of E2; E2R, or E2TR and E8/E2, with molecular masses of 31 
and 28 kDa respectively (70,(87).  Papillomavirus E2 proteins are comprised of 3 
distinct functional domains (see Figure I.2).  The N terminal region is necessary 
for interacting with proteins required for transcriptional activation, viral genome 
segregation, and DNA replication.  The C terminal is required for sequence 
specific DNA binding (6), and there is an intermediate region, referred to as the 
hinge region, which allows for flexible binding to both the DNA and N terminal 
targets (50).  Full length E2 (amino acids 1-410) encodes for all 3 of these 
regions.  The E2R protein (also known as E2-TR) contains only the DNA binding 
domain and includes amino acids 162-410 initiated from an internal methionine 
(85).  The E8/E2 protein is composed of amino acids 206-410 preceded by 11 
amino acids from the E8 ORF (87).   The N and C terminal domains are well 
conserved among papillomaviruses and their crystal structures have been 
determined (63, 66).  The hinge region is not well conserved across 
papillomavirus species and to date no structural data is available.   
The regulation of the E2 repressor proteins is controlled from distinct 
promoters located at nucleotides 3080 (E2R) (85) and 890 (E8/E2) (22).  Initially 
transcription of full length E2 was shown to be directed from a promoter located 
in the region of nucleotide 2443 (68, 187).  However, it has since been shown 
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that promoters at 890 and 7940 also regulate expression of BPV E2TA (172).  E2 
regulates the production of its own transcripts through both activation and 
repression of its promoters. 
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Figure I.2 .  Cartoon structures of the BPV-1 E2 protein.  To the right are 
listed the molecular weights of the proteins.  The bottom panel is a schematic of 
the 3 regions of E2, the N terminal transactivation domain, the C-terminal DNA 
binding domain and the non-conserved flexible hinge region joining the two.  
Bent arrows are the promoters which regulate transcription of these gene 
products.  Transcription of E2 also initiates at P890 and P7940 (Not shown in 
figure) (103). 
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E2 activates transcription by binding viral DNA with its C-terminal DNA binding 
domain and transcription factors with the N-terminal transactivation domain 
(102).  Only binding of transactivation competent E2 homodimers will result in 
activation of transcription.  Interaction of E2 with factors such as p300, 
GPS2/AMF-1 and Brd4 have all been shown to contribute to E2 mediated 
transcription of viral proteins (16, 105, 115).  Transcriptional activation occurs 
through binding of E2 sites adjacent to the promoter (153) as well as through 
binding to distal sites in the genome (163).  Activation through binding distal to 
the E2 promoter can be weak, but is strengthened through addition of binding 
sites or addition of a single binding site adjacent to the promoter.  Bending of 
bound DNA is believed to be required to bring the proximal and distal sites 
together and initiate activation (163).   
Repression of transcription by full length E2 also occurs. When expressed 
at high levels, E2 will bind to lower affinity sites denying access to cellular 
factors, such as Sp1 and TFIID, required for activation (159).  Preferential 
binding to higher affinity sites will lead to transactivation in the presence of low 
levels of E2.  E2-E2R heterodimerization also results in a repressor function for 
E2 (8). 
 
E2 recognizes a specific DNA sequence, ACCN6GGT (6) which is present 
12 times in the bovine papillomavirus genome, with 5 sites that display similar 
consensus and also bind E2 (Figure I.3)(94). Of these 17 sites the majority are 
located in the BPV-1 LCR and their affinities for the E2 consensus sequence 
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varies 300 fold.  The number of E2 binding sites also varies among 
papillomaviruses, with HPV 16 and 18 genomes only containing 4 binding sites, 
all located in the viral LCR.  Both full length E2 and the E2R protein bind a single 
recognition sequence as homodimers through the C-terminal DNA binding 
domain which is also the region required for dimerization (36, 114).   
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Figure I.3.   E2 Binding Sites in the BPV1 Genome.    The E2 binding  
          sites in the BPV1 genome are labeled 1-17.  The origin of  
          replication and E1 binding site is marked by a filled circle. 
          The open reading frames in BPV-1 are shown above.  
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In addition to its role in transcription, E2 also has roles in initiation of viral 
replication and in localizing the viral genome to genomic DNA during cell division.  
Activation and replication are separate and distinct functions of E2, and although 
increased transcription of viral proteins also leads to increased replication in 
transient replication assays, the transactivation function of E2 is not required for 
replication (178).  Additional roles of E2 will be discussed further in later 
chapters.  
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Topographic Localization of Bovine Papillomavirus E2 Protein 
During the Cell Cycle 
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 The multi-functional papillomavirus E2 protein plays important roles in viral 
replication, transcriptional activation and genome maintenance while the viral E1 
protein, a replicative helicase, functions solely in the initiation of viral replication.  
The bovine papillomavirus genome contains a single E1 binding site at the origin 
of replication, in addition to seventeen sequence specific E2 binding sites largely 
concentrated within the long control region.  In this study we have examined the 
association of both E2 and E1 with their specific binding sites throughout the cell 
cycle utilizing a murine cell line that stably expresses episomal bovine 
papillomavirus genomes.  Using chromatin immunoprecipitation (ChIP) followed 
by restriction enzyme digestion and PCR, we were able to determine the E1 and 
E2 binding site occupation during different phases of the cell cycle.  BPV E1 was 
found located only at the origin and on replicating DNA, while BPV E2 remains 
associated with specific sites on the genome throughout the cell cycle.  
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The Papillomavirus E1 Protein 
  
The papillomavirus early proteins E1 and E2 have been shown to be the 
only viral proteins required for transient replication of the genome (111, 146, 
171).  The E1 ORF is the largest in the 8 kb papillomavirus genome and is also 
the most highly conserved, producing a protein that averages about 650 amino 
acids with molecular weight in the range of 68-76 kDa.   E1 functions as an ATP 
dependent replicative helicase that binds, unwinds, and replicates the viral DNA 
(reviewed (148, 157, 164, 185).  E1 has been found to have three distinct 
domains:  the N terminal, whose function has not been clearly defined in HPV, a 
central linker region, and a highly conserved C-terminal region.  All of the 
functions required for DNA replication for human papillomaviruses have been 
mapped to the C terminal domain (44, 162).    In BPV1 these functions appear to 
spread across the 3 domains of E1.  The crystal structure of the DNA binding 
domain of BPV1 and HPV18 E1 have been determined (7, 40), and for HPV18 
the structure of E1 in complex with E2 has also been resolved (2).  Additional 
structures for BPV1 E1 have yet to be determined.  As there seems to be a 
reasonable difference between BPV1 E1 and HPV E1, for simplicity, and since 
the experiments in this thesis use a BPV1 model, the structural data referenced 
will be for BPV1 E1, unless otherwise stated.   
The location of the DNA binding domain of BPV1 E1 has been published 
by several groups (19, 92, 164).  Although there has been conflicting data 
published, it is most likely that the DNA binding region lies between amino acids 
121 and 311.  In addition to its DNA binding, E1 also specifically binds BPV1 E2.  
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This binding requires three distinct regions of E1, two that bind the E2 
transactivation domain (TAD) and one that binds the E2 DNA binding domain 
(DBD) (10, 11, 19, 113).  The purpose behind the multiple E1-E2 interactions 
appears to be the generation of specificity of E1 binding.  The E2 DBD is 
sequence specific and it binds to its site at the origin of replication, bringing the 
low affinity DBD of E1 to the DNA.  The TAD of E2 is thought to bind the helicase 
domain of E1, preventing that region from binding the DNA non-specifically, but 
with higher affinity, until it’s required (157, 158).   
In a cell free system E1 can initiate DNA replication in the absence of the 
viral E2 protein (99) and while E1 is capable of binding DNA with little or no 
sequence specificity, DNA binding to the BPV1 origin is stimulated by the 
interaction with E2, and required for DNA binding in vivo (99, 100, 146, 147, 170, 
186).  The current model suggests that E1 and E2 bind cooperatively to the viral 
origin of replication, with E1 binding as a head-to-head monomer, then as a 
double trimer. E1 hydrolyzes ATP and displaces E2, then begins to melt and 
unwind the DNA while additional E1 molecules are attracted to form the double 
hexameric complex at the origin (135, 144). 
 E1 has been shown to interact with several cellular replication factors.  
Topoisomerase 1, a factor required for relieving torsional stress incurred by the 
unwinding of DNA, has been shown to interact with both E1 and E2 and to 
enhance binding of E1 to the viral origin, although the exact mechanism of action 
is not yet clear (24, 25, 70).  E1 has also been shown to interact with replication 
protein A (RPA) a single-strand DNA binding protein required for replication on 
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the lagging strand of DNA (61, 107).    DNA polymerase  primase, required for 
primer synthesis, has been shown to interact with E1 (15, 125, 154).   DNA 
polymerase , theorized now to be required mainly for lagging strand replication 
(reviewed (84)), but known to share the majority of replication responsibilities 
with DNA polymerase has also been shown to be required for BPV DNA 
replication, as have replication factor-C (RF-C), the clamp loader,  and PCNA the 
sliding clamp (107).     
 While the minichromosome maintenance protein complex (Mcm2-7) and 
origin recognition complex (Orc) have been shown to be required for cellular 
DNA replication, neither protein has yet to be shown to be required for 
papillomavirus genome replication.  It has been reported that the HPV E6 protein 
from multiple types binds to the Mcm7 protein subunit and can induce its 
expression, as well as degrade it through the E6AP ubiquitin ligase (81, 83, 149).   
It is not known if cellular licensing factors, such as Cdt1, play a role in 
papillomavirus DNA replication.  However, bovine papillomavirus replicates in a 
random choice method where some genomes are duplicated multiple times per S 
phase and others not at all (48, 118).  This would seem to indicate that the virus 
has found a method to undermine the licensing process.  
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BPV1 E2 and Viral Replication 
 The role of E2 in transcription and its interactions with E1 have been 
previously discussed.  However there are some additional points which will now 
be addressed regarding BPV1 E2 and viral replication.   
The bovine papillomavirus type 1 (BPV1)  has been widely used as a 
model system for the study of replication and maintenance in PV.  When 
expressed in murine cell lines grown in monolayer, the BPV1 genome is able to 
persist episomally, displaying a stable copy number and expressing the essential 
early viral proteins.  Comparatively, the study of episomal human 
papillomaviruses (HPV) can be more problematic, with the majority of commonly 
used cell lines containing integrated HPV sequences.  The murine C127 cell line 
can be transformed by the BPV1 genome, leading to the expression of only 
extrachromosomal viral DNA, allowing for examination of replication without 
contamination from integrated genomes (88). The mechanism of this rodent cell 
transformation by BPV1 is still not fully understood, however the BPV1 E5 and 
E6 proteins can transform these cell lines (12, 142).  
Studies of the BPV1 genome identified 17 sequence specific E2 binding 
sites (94), the majority of which are clustered in the long control region (LCR), 
also called the upstream regulatory region (URR) of the viral genome.   Several 
binding sites are also found outside the LCR within the coding sequences of both 
the E1 and E2 genes.  Binding sites 11 and 12 (BS11 and BS12) flank the viral 
origin of replication, and as such they have been extensively examined.  In 1993 
Lusky, et al used cloned fragments of LCR in EMSA to determine that either 
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BS11 or BS12 were required for cooperative binding of BPV E1 and E2 to the 
origin of replication (99).  They also showed that increasing the distance between 
BS12 and the origin, from the wild type 9 nucleotides to 12, decreased 
association of E1 with the origin, while reducing from 9 to 6 nucleotides had no 
effect on E1/E2 cooperativity. Using baculovirus produced E1 they went on to 
show that in the presence of the intact BS12 E2 enhanced binding of the E1 
protein 40 fold and induced unwinding of the DNA (148).  In 1994 this same 
group demonstrated that 2 separate complexes could be isolated on the origin in 
vitro in the presence of plasmid DNA and baculovirus protein.  The two 
complexes that were discovered were E1 and E2 dimers together, or E1 
multimers.  This gave rise to a model similar to the current model for origin 
assembly where E2 is not maintained at BS12 following initiation of viral 
replication (see figure 1.1) (100). 
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Figure 1.1  Origin Binding of BPV1 Replication Proteins   An early          
         model proposed by Lusky, et al 1994 (100), detailing 
the positioning of E1 and E2 on the viral origin with removal of     
E2   required for replication. 
 
 
 
 
 
  35 
 
 
 
 
 
 
 
 
 
 
 
 
  36 
 
While the above work was being accomplished in vitro, Ustav, et al was 
asking the same questions using an in vivo system.  Using transient transfection 
of plasmid DNA in CHO cell lines expressing E1 and E2, they were able to show 
that high affinity E2 binding sites at a distance from the origin of replication were 
able to initiate transient replication in addition to the low affinity BS12 located 
adjacent to the Ori (170). 
In addition to its roles in replication and transcriptional regulation, E2 is 
required for securing the viral genome to mitotic cellular DNA (72, 90). This 
process ensures perpetuation of papillomavirus infection in dividing cells and cell 
culture systems by preventing loss of episomes through dissociation during 
breakdown of the nuclear envelope in mitosis (90).  Proper segregation of the 
viral genome during mitosis requires both cis and trans factors. The cis 
requirement for proper distribution of the episome consists of a region of the viral 
DNA containing a cluster of E2 binding sites termed the minichromosome 
maintenance element (MME) (3, 90, 131). The MME is located in the region of 
viral nucleotide 7600.  The E2 protein serves as the trans element and binds the 
viral genome through its C-terminal DNA binding domain, while additional cellular 
factors that facilitate genomic distribution bind to the N-terminal transactivation 
domain (3). The nature of these additional factors remains unresolved; our lab 
has reported that ChlR1, a DNA helicase, is required for the stable maintenance 
of the papillomavirus genome (123).  Other labs have reported that introduction 
of a dominant negative mutant of the bromodomain protein Brd4, a protein 
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reported to play a major role in regulation of E2 mediated PV transcription, (105, 
145, 179), results in disassociation of the viral genome from chromatin (190),  
In this study we used a modified ChIP assay to elucidate occupancy of E2 
consensus sequences on the BPV1 episome in a cell line that stably expresses 
the viral genome. Published data suggests that E2 is released from the genome 
following replication; however the question would then be what happens to E2 
between G1/S and mitosis? We asked whether E2 association with its binding 
sites varies during the cell cycle.    
We analyzed binding of E2 to its genomic sequences using chromatin 
immunoprecipitation (ChIP) of cross-linked protein/DNA complexes in 
synchronized cells.   In addition, the association of Brd4 with the viral genome 
through the course of the cell cycle was also examined. 
Using the replication factors known to be required transiently by BPV in 
vitro and those known to be required for Epstein Barr virus replication, we 
attempted to use  a standard ChIP assay to compare the proteins isolated at the 
viral origins at the onset of S phase.  Since EBV replication is restricted to once 
per cell cycle, it would interesting to see if licensing factors known to restrict 
cellular DNA replication were responsible for limiting EBV genome replication 
and not papillomavirus.  The pre-replication complex (pre-RC), the origin 
recognition complex (ORC), and the mini-chromosome maintenance complex 
(Mcm) have all been shown to be factors required for EBV replication (18, 34, 
141).  
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In some of these experiments our ChIP protocol was modified to include 
restriction enzyme digestion following the immunoprecipitation.  Digestion was 
undertaken with endonucleases targeting specific sites between E2 binding 
regions in the LCR sites and throughout the remainder of the viral genome. Then, 
specific polymerase chain reaction (PCR) primers were used to differentiate the 
bound regions of the DNA.  The original protocol utilizes only sonication to 
stochastically disrupt genomic DNA.  Our modification provides specific 
discriminate DNA sectioning and allows for finer resolution of binding site usage 
compared to sonication alone.  With this assay, we were able to show binding of 
E1 and E2 to specific regions of the episome in different phases of the cell cycle 
and to locate E1 in the region of the origin at initiation of viral replication. 
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Materials and Methods 
Cell culture.     The C127 A3 cells were a generous gift from M. Botchan.  ID13, 
A3 and C127 cells were all cultured at 37 C in Dulbecco’s Modified Eagle 
Medium (Gibco) with 10% fetal bovine serum, penicillin/streptomycin (100 U/ml) 
in 5% CO2.  1.4 X 10
6 A3 cells were plated in a 10 cm dish and 24 hours later 
were synchronized using 5 mM thymidine (Sigma) for 12 to 16 hours (G1/S) or 
100 ng/ml nocodazole for 12 hours (M).  
 
Chromatin immunoprecipitation (ChIP).  ChIP was performed using a protocol 
modified from Upstate Cell signaling.   A3 cells were synchronized overnight and 
cross-linked by the addition of formaldehyde (Sigma) (final concentration of 1%).  
Cells were incubated for 10 minutes at 37ºC, and washed with cold phosphate 
buffered saline (PBS) and scraped into a 1.5 ml collection tube. Nocodazole 
synchronized cells were collected using mitotic shake-off washed with cold PBS 
and centrifuged at 1000 g.  Cells were resuspended in 250 l lysis buffer (1% 
sodium dodecyl sulfate (SDS), 10mM EDTA and 50 mM Tris-HCl, pH 8.1) and 
incubated on ice for 10 minutes.  Lysed cells were sonicated for 50 seconds in 
10-second pulses at 30% output (Fisher Scientific dismembrator), and then 
centrifuged at 14000 g for 10 minutes at 4 C. The supernatant was  removed and 
diluted 10 fold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM 
EDTA, 16.7 mM Tris-HCl, pH 8.1, 167mM NaCl, PMSF, Roche complete 
protease inhibitor).  The ChIP lysate was pre-cleared by the addition of 30 l 
protein A agarose bead slurry (Upstate Cell Signaling) and incubation at 4 C, 
  40 
 
with agitation, for a minimum of 1 hour.  After centrifuging, the supernatant was 
removed and added to 50 l fresh beads containing 5 l II-1 rabbit anti-E2 
antibody, 10 l rabbit pre-immune serum, 3 l anti-EE ascites, 20 l monoclonal 
B202 supernatant, or 10 l anti E1 rabbit Ab. Following overnight incubation at 
4 C beads were pelleted at 4000 rpm and washed with cold low salt wash buffer 
(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris HCl, pH 8.1, 150mM 
NaCl), high salt wash buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM 
Tris HCl, pH 8.1,  500mM NaCl),  LiCl wash buffer (0.25M LiCl,  1% NP40, 1% 
deoxycholate,  1mM EDTA,  10mM Tris HCl, pH 8.1), and  twice with cold TE 
buffer (10mM Tris-HCl, 1mM EDTA, pH 8.0).  Complexes were then released 
from the beads using two 15 minute incubations with 250 l elution buffer (1% 
SDS, 0.1M NaHCO3).   The eluates were combined and reverse crosslinked by 
incubation with NaCl (final concentration of 0.2M) at 65 C for 4 hours.  Samples 
then were digested with 20 g proteinase K (Invitrogen) at 45 C for 1 hour with 
the addition of EDTA to 0.01M and Tris HCl, pH 6.5, to 0.04M.  DNA was 
recovered using phenol/chloroform/isoamyl alcohol extraction and overnight 
isopropanol/ethanol precipitation at -20 C.  DNA was re-suspended in water and 
analyzed by PCR. 
 
For restriction enzyme digestion coupled ChIP, samples were cross-linked with 
0.33% formaldehyde and ChIP was performed as described above.  Following 
immunoprecipitation and washing, samples were resuspended in 100 l of the 
appropriate restriction enzyme digest buffer, BSA and either 3 l of BanII (New 
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England Biolabs), 1 l high concentrate BglI (Promega), 1µl of both BglI and 
PflM1 (New England Biolabs), or no enzyme.  Restriction digests were then 
incubated at 37  overnight.  Following digestion, samples were washed twice 
with TE buffer and the sample recovery continued as described above. 
 
Re-ChIP.  Sequential Re-ChIP.  ChIP with restriction digest was initiated as 
previously described and continued through washing.  Wash buffer was removed 
and 60 l 1% SDS NaHCO3 elution buffer added.  Buffer and beads were 
removed to a fresh PCR tube and eluted in a PCR machine at 68º C for 10 
minutes.  The machine was paused every three minutes for gentle agitation of 
the samples.  ChIPs were centrifuged at 3000g for 5 minutes,  then the  
supernatant was removed and 950 l of ChIP binding buffer added (recipe as 
described above, but without SDS)  along with 30 l Sepharose beads.  Samples 
were pre-cleared for 1 hr at 4ºC with rotation.  Agarose beads were precipitated 
at 1000g and supernatants transferred to new 1.5 ml tubes.  While pre-clearing, 
the secondary Ab was bound to beads at 4º C using binding buffer without SDS 
and the appropriate concentration of secondary or control antibody.  The 
supernatant was removed from the pre-bound Ab/bead mix and the pre-cleared 
ChIP added.  Tubes were incubated ON at 4º C with rotation.  ChIPs were 
washed 1X each with low salt wash buffer, high salt wash buffer, LiCl buffer and 
2X with TE buffer.  The standard protocols for elution, reverse cross-linking and 
DNA purification were followed following the washes.              
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 Subtractive Re-ChIP.  ChIP was initiated as described for ChIP with 
digestion.  Following ON digestion supernatant was removed and beads 
discarded.  Supernatant was pre-cleared with beads for 2 hrs at 4º C.  The 
agarose beads were pelleted and the supernatant removed to a new tube.  Fresh 
agarose beads along with the appropriate antibody were added and the samples 
were incubated 4º C ON with rotation.  ChIPs were then washed, eluted, reverse-
crosslined and the DNA was purified as previously described. 
 Antibody crosslinking.   Protein A Sepharose beads (Upstate) were 
washed two times with PBS and 5 µl antibody per 1 ml bead slurry were added 
and mixed with rocking for one hour at room temperature.  The beads were then 
washed two times with 10 volumes borate buffer (0.2M pH 9) and were 
resuspended in 10 volumes borate buffer with the addition of powdered dimethyl 
pimelimidate dihydrochloride (DMP) to 2 mM (52 mg/10 ml). Antibodies were 
incubated another 30 minutes at room temperature with rocking.  The reaction 
was stopped by the addition of 0.2 M ethanolamine, pH 8. The beads were 
pelleted to remove the stop solution, then washed again with 0.2 M 
ethanolamine.  Washing was followed by incubation for two hours at RT, with 
rocking, in ethanolamine.  Crosslinked beads were then washed twice with PBS 
and stored at 4 ºC.     
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PCR Primers for Topographic mapping experiments.    
Primer Sequence Extension 
Temp for PCR 
Origin 
Primer Set A 
Forward 
Reverse 
tcaaaatgcagcattatattttaagct 
tggaacaccttgccaaagtcttc 
52 ºC 
Upstream E2 
Binding Region 
Primer Set B 
Forward 
Reverse 
acacccggtacacatcctgt 
ctgtctgtagtttaaggcg 
50 ºC 
BPV LCR 
Primer Set C 
Forward 
Reverse 
aaagtttccattgcgtctgg 
gctttttctagttagctggctatttt 
54 ºC 
BS 16 and 17 Forward 
Reverse 
ggtggtagaggtggagtttgatg 
agtagtagagcccagttccgtcag 
54 ºC 
L1 Forward 
Reverse 
atctccctccaacccctgtaag 
gcctgtttgtttcctgtcatctg 
50 ºC 
 
 
The PCR conditions were primer dependent.  The required number of cycles 
often varied between antibodies.  Primer Set C most commonly averaged 25 
cycles, with E1 requiing 2-5 more cycles to visualize product, and nocodazole 
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blocked cells also requiring additional PCR cycles.  The negative control samples 
were always run with the highest number of cycles used for any condition. 
 
FACS. A3 cells were synchronized as described and then fixed for flow 
cytometry.  Briefly, thymidine blocked cells were washed with PBS and 
trypsinized to collect.  Trypsinized cells were washed once in DMEM with FBS, 
twice in PBS, and centrifuged at 1000g.  The cell pellet was re-suspended in 
200 l ice cold PBS and gently agitated while 800 l ice cold 100% ethanol was 
added drop-wise and left at 4 C overnight to fix.  Following fixation cells were 
centrifuged at 1500 rpm for 5 minutes and fixation buffer was removed.  Samples 
were resuspended in 1ml of propidium iodide (PI) staining solution (glucose 1g/L, 
RNAse A 100U/ml, propidium iodide 0.05 mg/ml in PBS sample buffer (PBS, 
glucose 1g/L)).  Prior to FACS analysis (Becton Dickinson) samples were 
incubated in the dark at room temperature for 30 minutes and filtered through 
gauze.  Data was analyzed using FlowJo.   
 
Antibodies.  Rabbit anti-BPV E1 antibodies INA, 1C1, 502-2  in serum (137) and 
rabbit anti-BPV E2 antibody II-1 (6) were used for ChIP along with monoclonal 
antibodies to EE and E2 (B201 and B202) in cell culture supernatant.  The 
concentration of these antibodies has not been determined.  The amount of each 
required for ChIP was determined empirically.  II-1 requires 5 l and 502-2 needs 
10 l. Anti-Brd4 rabbit antibody used is AP8051a (Abgent), 5µg/ChIP.  
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Results 
The C127 A3 cell line stably replicates and maintains BPV1.  The 
episomal BPV genome contained within the C127 A3 cells contains three serine- 
to-alanine mutations in the hinge region of the E2 protein at amino acids 290, 
298 and 301.  These mutations stabilize E2 and increase genome copy number, 
as compared with wild type BPV immortalized cells (90, 91).  This appears to be 
due to lack of phosphorylation, mainly on serine 301.  This virus also fails to 
produce the E2R form of the E2 protein which may also result in increased E2 
levels and increased viral copy numbers due to lack of repression. 
In order to initiate the ChIP studies in C127 A3 cells it was first necessary 
to test the efficacy of the available antibodies to the BPV1 proteins.  A rabbit 
antibody to E2 (II-1) was raised in this lab and was used in detection of the 
protein from ID13 cells, the A3 cell line, or the parental C127 cell line.  As shown 
in figure 1.2, the E2 protein was immunoprecipitated from both BPV expressing 
cell lines using B201 mouse monoclonal anti-E2 antibody with detection by the 
rabbit antibody II-1.  It is interesting to note that the C-terminal repressor form of 
E2 (E2R) was not detected in the A3 cell line.  
A band representing BPV E1 was readily visible in both the A3 and ID13 
synchronized cells but not the parental C127 cell line (figure 1.3) after IP and 
immuno-blot with the 502-2 rabbit antibody.  The E1 protein is expressed at very 
low levels in in vivo systems and historically has been difficult to detect.   
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Figure 1.2.   E2 Immunoprecipitation in A3 Cells. 
 A3, ID13 and C127 cells were immunoprecipitated with the mouse 
monoclonal antibody B201 with western blot performed using rabbit 
antibody II-1.  The top arrow indicates the band for E2, the bottom 
the repressor form   E2R.  Samples on the right contain 5% input. 
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Figure 1.3.   E1 Immunoprecipitation in A3 Cells. 
BPV1 E1 was immunoprecipitated from A3, ID13 or the  
  C127 parental cell line with the 502-2 rabbit antibody.  The  
  immunoblot was performed using a 1:500 dilution of  
  502-2 and developed using the Thermo-Pierce Dura kit. 
64 indicates the location and size of the 64 kDa band in the 
marker used (See Blue II-Invitrogen). 
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Utilizing the antibodies for both BPV1 E1 and E2, we undertook to ChIP a 
segment of PV DNA encompassing the viral origin and several of the surrounding 
E2 binding sites.    Pre-immune rabbit serum was used as a negative control for 
the rabbit II-1 ChIP, and antibody against the EE epitope used as a negative 
control for ChIP with the monoclonal E2 antibody B202.  Both the E1 and E2 
ChIPs were clearly positive for BPV origin DNA after 25 cycles of standard PCR 
using primers located near E2 binding site number 5 within the long control 
region and downstream of the BPV origin (Primer set C) (Figure 1.4).   
The BPV1 E1 protein is expressed at low levels in cells that stably 
replicate viral episomes.  Using asynchronous A3 cells, ChIP was performed 
using anti-BPV1 E1 antibodies developed in this lab (Figure 1.5) Antibodies were 
used to detect E1 on the viral genome, utilizing II-1 Ab for E2 as a positive 
control compared to rabbit pre-immune serum and EE antibody as negative 
controls.  The N-terminal peptide antibody 1NA, and two C-terminal peptide 
antibodies 1C1 and 502-2, co-precipitated the BPV origin in asynchronous cells 
using standard PCR with primer set C.  This places E1 adjacent to the viral origin 
at the initiation of BPV replication in vivo. 
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Figure 1.4     E2 Chromatin Immuprecipitation in A3 Cells. 
The BPV1 LCR region was isolated in asynchronous A3 cells using 
chromatin immunoprecipitation.   Lane 2-E2 ChIP with rabbit serum 
antibody II-1. Lane 3-Rabbit pre-immune serum. Lane 4-ChIP with 
E2 mouse monoclonal antibody B202 supernatant. Lane 5- EE 
monoclonal antibody ChIP.  Lane 6-1% Input. Primer set C for the 
viral LCR was used to amplify ChIP DNA.  The molecular weight 
marker is a 100 bp ladder in Lane 1 and contains a darker band at 
500 bp.  Lane 7-Negative control for the PCR contains no DNA. 
Lane 8-Positive control is the BPV1 genome purified from E. Coli 
DH5α.  
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Figure 1.5  E1 Chromatin Immunoprecipitation in A3 Cells. 
BPV1 LCR is identified in a chromatin immunoprecipitation assay 
using IP with anti-E1 antibodies and PCR using primer set C for the 
viral LCR.  Lane3-1NA Rabbit antiserum; Lane 4- 1C1 rabbit 
antiserum; and Lane 5-502-2 rabbit antiserum.  The positive control 
used is Lane2-E2 II-1 rabbit; and the negative controls include both 
Lane 7- rabbit pre-immune serum; Lane 8- the anti EE monoclonal 
antibody.  Lane 9- is PCR negative without DNA; Lane 10-The 
positive control is bacterially expressed papillomavirus genome.  A 
100 bp marker is included in Lane 1 with the darkest band at 500 
bases. 
  
 
 
 
 
 
 
 
 
 
 
 
 
.                  
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To determine whether both E1 and E2 were associated with the viral 
genome in cycled cells, A3 cells were chemically treated to prevent progression 
through the cell cycle and allow for synchronization.  The cells were effectively 
blocked in G1/S using 5 mM thymidine (16 hours) or G2/M with 100 ng/ml 
nocodazole (12 hours).  As shown in Figure 1.6A, both the thymidine and 
nocodazole blocks resulted in well defined peaks when examined using flow 
cytometry, while sub-confluent asynchronous cells were distributed throughout 
the cell cycle, with the majority in G1.  ChIPs performed on these synchronized 
cells illustrated the ability to detect E2 in G1/S, ansynchronous cells (Figure 1.4) 
and cells blocked at G2/M (Figure 1.6B).  In contrast, E1 only associated with 
viral genomes in asynchronous or G1/S blocked cells, but not in cells blocked in 
mitosis.  Figure 1.6.C. shows that E1 is not detectable in mitotic A3 cells. 
The binding site usage of E2 during the cell cycle in A3 cells was also 
assessed. The majority of E2 binding sites in the BPV genome are located in the 
LCR with some as few as 17 bases apart, as illustrated in Figure 1.7.  In order to 
ensure interruption of the viral genome specifically between these LCR binding 
sites a restriction enzyme digest was added to the ChIP protocol.   The BPV1 
LCR was examined for restriction enzyme digestion sites that would specifically 
release the origin of replication from upstream E2 binding sites.  Sites for BanII 
and BglI were chosen for ChIP due to optimal location in both the LCR and entire 
genome (Figures 1.7 and 1.10). 
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Figure 1.6.A. Flow cytometry of A3 cells blocked in the cell cycle.  The 
foremost graph are cells synchronized in G1/S using 5mM 
thymidine.  Cells in the center graph are blocked at pro-
metaphase using 100ng/ml nocodazole.  The back line 
depicts asynchronous A3 cells.  
         
 
 
 
 
 
 
Figure 1.6.B  A3 cells are synchronized as described above and submitted 
for ChIP assay using primers for the viral LCR (primer set 
C).  Lane 1-100 bp marker; Lane 2-E1 in A3 cells blocked in 
G1/S; Lane 3-E2 G1/S; Lane 4-pre-immune serum in G1/S; 
Lane 5-E1 in G2/M blocked cells; Lane 6-E2 in G2/M cells; 
Lane 7-pre-immune serum in G2/M; Lane 8-E1 in 
asynchronous cells; Lane 9-E2 in asynchronous cells; Lane 
10-pre-immune serum in asynchronous cells; Lane 11-
negative PCR control; Lane 12-bacterially purified DNA. The 
502-2 antibody was used for detecting E1; II-1 for E2.  
 
 
Figure 1.6.C. C127 or A3 cells were synchronized as described and 
harvested for immunoblot of BPV-1 E1 using antibody 502-2.  
Lane 1-C127 blocked in G1/S;  Lane 2-A3 G1/S; Lane 3-A3 
asynchronous; Lane 4-A3 G2/M.  A line depicts the position 
of the 64 kDa molecular weight marker.      
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Figure 1.7  Nucleotide sequence of the BPV1 LCR.  As shown below E2 
binding site are in bold, with the E1 binding site/origin of replication 
underlined.  E2 BS11 and BS12 flank the origin.  Several 
endonuclease digestion sequences are highlighted.  This  
 sequence encompasses nucleotides 7140-80. 
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7141
agtcaactgcacctaataaaaatcacttaatagcaatgtgctgtgtcagttgtttattggaaccacaccc
ggtacacatcctgtccagcatttgcagtgcgtgcattgaattattgtgctggctagacttcatggcgcct
ggcaccgaatcctgccttctcagcgaaaatgaataattgctttgttggcaagaaactaagcatcaatggg
acgcgtgcaaagcaccggcggcggtagatgcggggtaagtactgaattttaattcgacctatcccggtaa
agcgaaagcgacacgcttttttttcacacatagcgggaccgaacacgttataagtatcgattaggtctat
ttttgtctctctgtcggaaccagaactggtaaaagtttccattgcgtctgggcttgtctatcattgcgtc
tctatggtttttggaggattagacggggccaccagtaatggtgcatagcggatgtctgtaccgccatcgg
tgcaccgatataggtttggggctccccaagggactgctgggatgacagcttcatattatattgaatgggc
gcataatcagcttaattggtgaggacaagctacaagttgtaacctgatctccacaaagtacgttgccggt
cggggtcaaaccgtcttcggtgctcgaaaccgccttaaactacagacaggtcccagccaagtaggcggat
caaaacctcaaaaaggcgggagccaatcaaaatgcagcattatattttaagctcaccgaaaccggtaagt
aaagactatgtattttttcccagtgaataattgttgttaacaataatcacaccatcaccgttttttcaag
cgggaaaaaatagccagctaactataaaaagctgctgacagaccc
80
Bold = E2 binding sites
underlined = E1 binding site        Bgl1 site Hpa1  Sau3A1  BanII
DpnI
BanI  
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Figure 1.8 Agarose gel of test digest using DNA digested with Bgl1.    
Primer set C was used to detect digested DNA.  Lane 1 is 100 bp 
marker, lane 2 is digested DNA and lane 3 is un-digested DNA.  All 
samples were crosslinked with 1% formaldehyde prior to harvest.
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Standard ChIP protocol requires the addition of formaldehyde to a final 
concentration of 1%.  It is possible that the addition of formaldehyde to the cells 
would crosslink the DNA and compromise the restriction enzyme site.  The initial 
test was to see if digestion could occur under these conditions using cell lysates 
that were then purified and analyzed by PCR.  Figure 1.8 is a test of this 
principal, and showed that the formaldehyde used did not interfere with the 
endonuclease digestion.   
Three sets of primers were designed to detect ChIP products from this 
region of the LCR as depicted in figure 1.9 and materials and methods.  The first 
set (A) amplified nucleotides 7867 to 297 surrounding the viral origin.  The 
second set of primers (B) encompasses nucleotides 7205-7685 and amplified 
DNA upstream of the BPV origin.  The third set of primers, primer set C, flanked 
both the BanII and BglI restriction sites from nucleotides 7522 to 67.  Digestion 
with BanII at nucleotide 7653 and BglI at 7832 facilitated the examination of the 
LCR close to the origin of replication, specifically allowing for detection of these 
separated regions by PCR.   Digestion at these sites was designed to delineate 
origin binding (primer set A) from upstream E2 binding sites (primer set B), with 
primer set C serving as a control for the ChIP and to demonstrate efficient 
cleavage by the endonucleases, as efficient cleavage at these sites prevented 
formation of a PCR product using primer set C (See diagram Figure 1.9).   
ChIP in combination with restriction enzyme digestion was applied to 
thymidine blocked A3 cells and binding to the BPV origin was subsequently 
examined by PCR.  The fragment of LCR amplified by primer set C was 
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precipitated by both E1 and E2 in undigested samples (Figure 1.9.C).  Digestion 
by both BanII and BglI resulted in absence of product amplification, due to the 
restriction sites dissecting the genome between the PCR primers (nucleotides 
7522-67), forming an efficient control for both ChIP and enzyme digestion.  
Figure 1.9.B. shows amplification of region B of the LCR upstream of the 
origin (7205-7685) from the thymidine blocked A3 cells. This region of the DNA 
contains multiple E2 binding sites (sites 1-10).  E1 did not bind this region of the 
viral genome in either digested or undigested samples.  However, E2 was 
detected at this region in undigested and BglI digested samples, but not in those 
subjected to BanII digestion due to the location of the PCR primers which flanked 
this cut site.  Nucleotides 7867-297 span BPV binding sites 11 and 12 as well as 
the BPV E1 origin of replication (Figure 1.9.A.).  PCR with primer set A detects 
both E1 and E2 bound to the genome at the origin of replication in cells blocked 
in G1/S.  The results from this panel of PCR primers indicate that, in S phase, E2 
binds to several sites in the viral LCR, binding upstream and remaining at the 
origin of replication.   
 
Panels D and E of Figure 1.9 demonstrate results obtained from ChIP of 
the LCR region in cells synchronized at early mitosis with nocodazole.   E2, and 
not E1, immunoprecipitates the genome in these cells.  Binding to the E2 cluster 
region of the LCR surrounding the MME, evidenced by a band in the BglI lane of 
1.9.E,  is faint, but may be indicative of  specificity in this region.  Binding is 
evident in the LCR (1.9.D). 
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To acquire a more complete picture of the association of E2 with the 
genome in cycling cells additional ChIP/restriction enzyme digestions were 
performed.  The restriction enzyme PflM1 (nucleotide 3682) was used in 
combination with BglI (nucleotides 618, 2818, 6531 and 7832) resulting in the 
absence of E2 binding sites in connection with the L1 coding sequence (See 
Figure 1.10).   
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Figure 1.9. E1 and E2 on the Genome in Cycled, Digested A3 Cells. 
The cartoon on the right depicts the primer scheme used to  
  determine where E1 and E2 immunoprecipitated on the viral 
genome in thymidine blocked cells following digestion with 
either Bgl1 or BanII.  Panel A was amplified using primer set 
A flanking the viral origin.  Panel B utilized primer set B to 
identify DNA precipitate from the LCR regions upstream of 
the origin and panel C encompassed both restriction enzyme 
sites and the origin as well as upstream E2 binding sites.   
 
Panels D and E are ChIP of nocodazole blocked cells with 
PCR for the upstream E2 cluster (D) or the entire LCR (E). 
   Letters on the right of diagram indicate primers used. 
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Figure 1.10 Restriction Enzyme Sites in the BPV1 Genome. 
Schematic of BPV1 genome including E2 binding sites BanII, BglI,  
  and PflMI sites.    
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The LCR was amplified  using primer set C in all undigested PCR 
reactions (Figure 1.11 lane 1, LCR), while the restriction enzyme controls using 
BglI digestion and LCR primers were all negative (lane 2 LCR). This 
demonstrated that the viral DNA was efficiently digested, at least in the LCR 
region.  Nucleotides 5638-6039 were amplified with primer set L1 (Figure 1.11, 
L1).  The E2 antibody did not ChIP this region in digested or undigested samples 
(Figure 1.11, lane 1) consistent with the absence of E2 binding sites (Figure 1.11, 
lane 2, L1). 
The sequence between the BglI restriction site at 2818 and the PflM1 site 
at 3682 contains E2 binding sites 16 and 17.  This region was amplified from the 
ChIP DNA samples using primers for nucleotides 2953-3085; however, the E2 
binding was absent in both undigested and in digested ChIPs (Figure 1.11, BS 
16&17).  Only faint binding was detected at any of the distal sites outside the 
LCR in any phase of the cell cycle, G1/S, asynchronous or mitosis, could be 
detected during these studies (compare A, B and C groups, Figure 1.11).   
Quantification of these PCR results using ImageJ software is shown in 
Figure 1.11.  While this PCR is meant to be qualitative, distinct differences can 
be observed between the positive E2 binding in the LCR when compared to both 
L1 and BS16&17.  The most significant positive outside the LCR is detectable in 
asynchronous cells in the L1 region.  Binding here is 7 fold lower than that 
detected in the LCR region of the genome in this sample.   
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Figure 1.11.  Off-origin ChIP of E2 in Cycled A3 Cells. 
A3 cells were synchronized   and ChIPped for BPV E2 (lane1), then 
ChIPped for E2 and digested with BglI and PflM1 (lane 2). Lane 3 is 
undigested ChIP sample using rabbit pre-immune serum, and Input 
diluted 1:10 is also shown (lane 4).  PCR was performed using 
either primers for the LCR of BPV, for nucleotides 5638-6039 in the 
L1 region (L1) or for nucleotides 2952-3085 flanking E2 binding 
sites 16 and 17 (BS 16&17).  Samples in 1.11.A. are synchronized 
at G1/S, 1.11.B. are asynchronous and 1.11.C. are blocked at pro-
metaphase. 
 
  
PCR samples were quantified using ImageJ software and the 
results shown below each panel.  Background was sub- 
tracted then samples were normalized to input.  Negative  
values were set at zero.   
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Brd4 has been shown to be responsible for tethering of the viral genome 
to cellular chromatin during mitosis (190).  There is some ChIP data illustrating 
binding of Brd4 to the viral genome, however it is unclear whether this data was 
obtained in mitotic cells (190).  We performed a ChIP assay on A3 cells to 
determine the genomic localization of Brd4 in mitotic A3 cells.  Figure 1.12 shows 
a ChIP assay for E2 and Brd4 in cycled A3 cells in the absence of restriction 
endonuclease digestion.  Results showed that Brd4 did not ChIP with the viral 
genome in either thymidine blocked cells (Figure 1.12.A.) or nocodazole blocked 
cells (Figure 1.12.C, lane 2).  However, association was detected in 
asynchronous cells (Figure 1.12.B, lane 2), consistent with a role for Brd4 in viral 
transcriptional regulation.  
 
In order to examine whether both E1 and E2 were bound to the viral origin 
simultaneously we attempted a re-ChIP of the BPV LCR (Figure 1.13).  ChIP 
samples were washed, eluted from the antibody, then another ChIP was 
performed using either the same antibody (positive control) a second antibody, or 
pre-immune serum (negative control).   
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Figure 1.12.  ChIP of Brd4 on the BPV1 genome.  Primer set C for the BPV 
LCR was used.  Lane 1 is II-1 E2  Ab; Lane 2 is Brd4; Lane 3 pre-
immune serum; Lane 4 is input.  The molecular weight marker is a 
100 bp ladder, with a darker band at 500 bases.  Panel A thymidine 
blocked (G1/S), Panel B asynchronous, Panel C nocodazole 
blocked (M).
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Figure 1.13 Re-ChIP 
Two separate attempts at a sequential re-ChIP of the LCR.  Anti- 
bodies are listed below figure in order of use. The E2 antibody II-1; 
E1 502-2; EE is monoclonal antibody to the EE epitope  
  tag.  The molecular weight marker is a 100 bp ladder, with the  
  darkest band at 500 bp. 
 
The bottom panels depict two successful re-ChIP experiments in 
A3 cells stalled at G1/S with 5mM thymidine.  
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High background occurred in all lanes in which E2 was used as the primary 
antibody.  Additional ChIPs were performed in thymidine blocked cells to see if 
the background could be cleared using additional high salt washes.  Two ChIPs 
showed minor background, with clean positives, but the results could not be 
repeated (Figure 1.13 bottom panel).  These samples are undigested ChIPs, and 
as such show only that E1 and E2 are on the same larger DNA fragment.  
Digestion would be required to determine whether these proteins are bound 
together near the origin.   
 In an attempt to reduce background the primary and secondary antibodies 
were both cross-linked to the Sepharose beads using dimethyl pimelinidate 
dihydrochloride (Figure 1.14).  No improvement was seen as a result of this 
additional step.   
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Figure 1.14 Cross-linked re-ChIP. 
A re-ChIP with antibodies that had been cross-linked to protein A 
Sepharose beads prior to immunoprecipitation. E2 anitbody used 
was II-1, E1 antibody 502-2.  Lane 1- 100 bp  marker with 
emphasis beginning at 500 bp; Lane 2-E2/E2; Lane 3-E2/E1; Lane 
4-E2/pre-immune serum; Lane 5- pre-immune serum/E2; Lane 6- 
  PCR(-) no template; Lane 7-PCR (+) plasmid DNA. 
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The ChIP assay was effective in the A3 cell line with the endogenous viral 
proteins E1 and E2.  We thought to broaden the study to examine cellular factors 
that might be present at the viral origin and required for BPV1 DNA replication.  
An EBV containing plasmid, pMEP was the positive control for these 
experiments.  In order to compare both viral origins, the A3 system was 
abandoned in favor of transfection into the C33a cell line.  The main advantage 
to working with C33a is that these cells are an adapted HPV negative cervical 
cancer line, allowing for use of antibodies to human replication proteins. The 
main drawback is that it is not known whether the BPV1 genome will replicate in 
this cell line.  Primers were constructed for real time PCR (RT) on both the pMEP 
plasmid and the BPV1 genome.  One g of each was transfected into a 10cm 
dish of C33a and cells were synchronized with 5 mM thymidine at 24 hours post 
transfection.  Cells were harvested at 36 hours and ChIP assay performed using 
5-10 g of antibody.  Quantitative RT was performed on the samples (Figure 
1.15).  ChIP on the transfected cell line did not give reliable results using 
quantitative PCR.  The same samples used for two real-time assays showed 
remarkably different results when the annealing temperature for the PCR was 
changed from 58  (left panel) to 60 C (right panel).  Results were calculated 
using fold increase over negative control, or arbitrary units of DNA.   
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Figure 1.15 ChIP of Replication Proteins in C33a Cells. 
The graph on the left is RT of C33a cells transfected with pMEP 
  and immunoprecipitated.  The antibody is labeled on the X-axis. 
  Y-axis shows fold increase over negative control.  The right graph 
  depicts the same samples with increased annealing temperature 
  of 60 vs 58, and with arbitrary units of DNA on Y-axis.  
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Discussion 
 
The results placing the E1 protein at the site of initiation of viral replication 
on the complete genome in a cell culture system are not unique. Nonetheless, 
along with the immunoblot data, the figures are interesting in that the levels of E1 
produced from the viral genome are so low that the protein is not normally 
detectable.  Here E1 was evident in both the A3 cell line and the ID13, and the 
ChIP results were measurable and repeatable.  We also show that E2 remains 
associated with the genome, regardless of the phase of cell cycle.  While 
extensive work has been undertaken to characterize the E2 binding sites within 
the genome of the bovine papillomaviruses, the majority of these studies utilized 
either in vitro systems or in vivo models where E1 and E2 or portions of the viral 
LCR were transfected into cell lines (21, 72, 95, 100, 111, 131).  Ustav et al. 
used mutated E2 binding sites, including BS12, and cell lines stably expressing 
both E1 and E2 to examine the requirement for E2 at the origin of replication 
(170). Sedman and Stenland use EMSA and DNAse I footprinting of E1 and E2 
expressed from E.coli to examine the binding of E1 and E2 to the viral origin 
(146).  Lusky et al. (100) and Yang et al. (186) developed cell free systems which 
utilized portions of the LCR combined with E1 alone (100) or E1 and E2 (186)  
and examined the effects of  mutations and variations and expression levels of 
E1 and E2.  Piirsoo et al used portions of the viral genome containing, or lacking, 
specific E2 binding sites and partially characterized E2 mutants to determine the 
cis requirements for the MME in stable maintenance (131).  These in vivo and in 
  84 
 
vitro models utilized E1 and E2 at levels notably higher than endogenously 
expressed protein and do not allow for the influence of the cell cycle on viral 
protein levels, expression, modification or nuclear localization.   
In comparison to the above, the method adapted by this lab utilizes the 
C127 A3 cell line that stably replicates the entire BPV1 genome with serine to 
alanine mutations in the E2 protein at amino acids 290, 298 and 301.  In wild 
type BPV1, phosphorylation, ubiquitination and degradation of E2 seem to rely 
heavily on phosphorylation at serine 301, and mutation of this serine alone 
results in raised levels of E2 which increases the availability of E2 for tethering 
during mitosis and enhances viral DNA copy number (91, 129).  This cell line 
also lacks the E2R repressor element often found in replicating wild type BPV1 
systems (Figure 1)(86).  This may lead to increased viral replication over wild-
type BPV1 systems.  The use of a stably replicating cell line, despite the 
mutations, allows for formation of nucleosomes on the viral genome and 
regulation of the viral gene products in a manner more consistent with in vivo 
systems when compared with previous studies. 
Traditional ChIP has been used to distinguish between closely aligned 
transcription factor binding sites within cellular genomic DNA utilizing only 
sonication to disrupt the chromatin. For our purposes sonication resulted in 
variable sized fragments with no consistent restriction points and in the majority 
of cases sonication alone was unable to disrupt the genome between the tightly 
packed E2 binding sites of the LCR.  This may be due to the size constraints of 
the BPV genome, or alternatively the traditional ChIP may have insufficient 
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resolution for differentiating between close DNA binding sites and subsequently 
may be more useful when examining promoters or other DNA elements 
separated by greater distances.  At a lower concentration of formaldehyde (.33%) 
sonication alone was able to separate the origin from the genome to some extent 
(Figure 1.9.B.), but proved to be inconsistent.   Therefore, the combination of 
traditional ChIP with restriction enzyme digestion ensured the specificity of the 
DNA binding by E2.  BPV1 E1 binds specifically to the viral origin and can be 
immunoprecipitated on this site in genomes initiating replication.  E1 can 
therefore serve as a positive control in future ChIP assays to examine cellular 
factors required for BPV1 replication.   
While the A3 cell line performed relatively well when synchronized, there 
were minor limitations imposed on this study by the irregularity of cycling.  Serum 
starvation did not maintain cells in G1, as a subpopulation continued to cycle 
(data not shown).   Thymidine blocks cells at the initiation of replication by 
inhibiting the synthesis of deoxycytidine and initiating the DNA repair response.  
This stalls the progression of replication forks and delays the transition into S 
phase (13, 181) and was employed here to analyze cells that were blocked at the 
border of G1/S at the initiation of viral replication. Our intent was to trap E1 and 
E2 at the onset of replication.  A double thymidine block is the more common 
approach, but a double block resulted in a significant amount of cell death with 
the A3 cell line. As shown in Figure 1.6.A. a single thymidine block resulted in the 
majority of cells blocked at G1/S.  Also, a significant number of the cells released 
from a single thymidine block would not progress into S phase along with the rest 
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of the population, despite repeated washing, resulting in asynchrony.  This made 
it impossible to collect data resulting from direct release from serum starvation or 
thymidine block and subsequent progression through the cell cycle, necessitating 
the use of nocodazole for examining cells blocked in mitosis.  Nocodazole acts 
as a microtubule depolymerizing agent and prevents assembly of the mitotic 
spindle required for genome segregation, effectively blocking cells in 
prometaphase.  This block does not interfere with BPV1 E2 mediated 
segregation of episomes, which is independent of mitotic spindle formation (30), 
nor should it interfere with Brd4 mediated attachment to chromatin, as Brd4 has 
been shown to localize to condensed chromatin with only minor staining visible 
on mitotic spindles (1, 190). 
 Although Brd4 is a potential candidate for the cellular protein required for 
viral tethering, neither our lab nor Ives et al were able to place Brd4 on the viral 
genome in mitotic cells using chromatin immunoprecipitation (71).  It is possible 
that the association of Brd4 with E2 and the viral genome prior to mitosis is the 
key to its role in tethering, or it is also possible that the assays employed are not 
sensitive enough to detect the interaction of this protein with the genome during 
prometaphase.  Our data is consistent with the published role for Brd4 in 
mediating viral transcription (71, 89, 105, 145, 179).   
Our data does show that E2 remains associated with the BPV LCR 
throughout the cell cycle, even appearing on the viral MME at G1/S in addition to 
binding near the origin of replication.  It has been reported that central LCR E2 
binding sites, predominantly sites 5-8, are the cis element required for BPV1 
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genome tethering (131).  Our results confirm that the E2 protein is specifically 
bound to the LCR of the viral genome in cells blocked at the onset of mitosis.   
BPV1 E2 binding sites 11 and 12 are found flanking the viral origin of 
replication.  It has been reported that the binding of E1 to the viral origin excludes 
E2 from BS12 (100).  Our data does not differentiate between binding to BS11 or 
to BS12 in cells blocked at G1/S (Figure 1.9); neither does it verify that E1 is 
present on the origin while E2 is bound to BS12.  The use of sequential ChIP of 
the origin would be necessary to show concurrent association of both viral 
proteins. Attempts at this technique were not effective due to high background, 
but initial data is promising.  Additional restriction enzyme digestion would also 
be required to differentiate between binding of E2 to sites 11 and 12, both of 
which have been shown to be capable of a role in initiating replication in vitro 
(136).   
The BPV E2 binding sites have been determined based on both sequence 
similarity and detection of E2 bound to DNA in vitro using electrophoretic mobility 
shift assay (EMSA).  The affinity of several of these binding sites is remarkably 
low, leading us to question their functionality.  The binding sites outside the viral 
LCR do not appear to be required for growth or maintenance of the monolayer 
cultured transformed cells. However, it is possible that they are utilized during 
growth of differentiated cells.   It is also interesting that the inability to detect the 
E2R mutant in A3 cells correlates with the absence of E2 at the putative E2R 
promoter, which is thought to regulate its expression.  Why the A3 mutant would 
not bind to this site in vivo is uncertain.   
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The herpesvirus protein Epstein Barr Nuclear Antigen 1 (EBNA-1) is 
similar in function to E2.  It too is multifunctional with roles in replication, 
transcription and viral maintenance.  The DNA binding and dimerization domain 
of EBNA-1 folds in a beta-barrel structure similar to E2 (reviewed in (54, 97)) and 
binds to the cellular protein Brd4 during mitosis (96).  The genome of EBV 
however is more than 20 times the size of the BPV genome and in contrast to the 
PV genome, which may replicate several times per S phase, replicates only once 
per cell cycle being subject to the restrictions of DNA licensing factors in the cell 
(97).  While ChIP assays have placed a number of cellular factors at the EBV 
origin (18), our lab is currently using this technique to compare these systems 
and determine the cellular factors required for PV replication in both monolayer 
and differentiated keratinocyte culture systems.  The C33a system has shown to 
be undesirable for determining origin binding of BPV because the positive and 
negative controls were not reliable and additional work would be required for 
optimization.  Instead of repeating EBNA results previously published, a negative 
control antibody will be used and E1/E2 will serve as reliable positive controls.  
 There are several technical points to keep in mind when performing the 
ChIP and restriction enzyme digest (RED-ChIP) assay.  Formaldehyde oxidizes 
quickly and should be used within 30 days of opening.   Precious time was 
wasted attempting to get the assays back on track after using old formaldehyde.  
Assuming fresh formaldehyde, only .33% final volume is required for RED-ChIP 
cross-linking as compared to the traditional ChIP.  The restriction enzymes need 
to be checked periodically as well.  Incomplete digestion was also another factor 
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in wasted experiments, especially with highly concentrated enzymes, which 
seem to become inactive more quickly than those of lower concentration. 
The use of ChIP combined with the restriction enzyme digest is a useful 
tool for finer mapping of transcription start sites in regions of the genome where 
these sites are within several nucleotides of each other with a restriction enzyme 
site between.  It may be possible, utilizing this technique, to analyze the binding 
of E2 to its sites in the genome in differentiated human keratinocytes containing 
the viral genome to determine the occupancy of E2 binding sites throughout the 
viral replicative program.  
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Work in this section was supplemented by Joanna L. Parish PhD and Angela M. 
Bean, a current graduate student at the University of Massachusetts Graduate 
School of Biomedical Sciences.  Portions of this work have been submitted for 
publication and are currently under revision. 
 
 
 
Association of Cohesin with the papillomavirus E2 protein and episomal viral 
genomes.   Joanna L. Parish, Suzanne M. Melanson, Angela M. Bean and Elliot 
J. Androphy.  Submitted J. Virol.
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E2 and the Cohesin Protein Scc1 
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The Cohesin Proteins 
 Upon completion of S phase, each cell contains two copies of its genetic 
information in the form of sets of sister chromatids. Cohesion, which is 
established during replication, ties newly replicated sister chromatids together 
until the onset of anaphase, where dissolution of the ties that bind allows for 
complete and perfect segregation of these chromatids into the newly forming 
daughter cells.  Correct and timely segregation of sister chromatids is essential 
for maintaining the eukaryotic genome. As mitosis approaches, the pairs of sister 
chromatids align along the metaphase plate.  The kinetechores of the sisters 
attach to opposite centrosomes through the mitotic spindles.  Only when each 
chromatid is aligned, and applying tension to its attached spindle, are the two 
able to separate through the dissolution of cohesion (Reviewed (119)).    Two 
methods of cohesion have been postulated, and it is possible that both are 
required for the proper maintenance of genome copy number.  The first method 
proposed was catenation (117).  Catenation involves the intertwining of genomes 
as a result of replication and physically ties the creation of cohesion to S phase 
of the cell cycle.  The second method, and the most widely subscribed to, 
establishes a biochemical link between S phase and cohesion and this method is 
the formation of the cohesin complex (57, 109).     
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Figure 2.1    Cartoon Depiction of Cohesin Structure. 
                      The cartoon depicts the structure of the cohesin complex with the    
N-C terminal heads of Smc1 and Smc3 binding to Scc1, with their 
tails forming the hinge region with a coiled coil structure in between.  
The large figure suggest cohesin engaging sister chromatids 
together, while the smaller insert suggests an alternate model  
                      where each cohesin ring binds one sister, with the cohesion being    
                      established  by the interaction of the two rings. 
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The cohesin complex is formed by the association of the proteins Structural 
maintenance of Chromosome 1 (Smc1) Smc3, and Scc1 in a trimeric ring-like 
structure (55).  The SA1 protein is also involved, in contact with Scc1, to form a 
structure large enough to encircle both sister chromatids engaged with histones.  
As depicted in figure 2.1, the heads of Smc1 and Smc3 are globular domains 
which function to bind ATP and Scc1.  The N-terminus of Scc1 binds the Smc3 
head with the C-terminus binding the Smc1 head. The hinge region, or tail, of 
Smc is required for dimerization of the SMC proteins (58).  A flexible anti-parallel 
coiled-coil domain connects the head and tail, with the N and C termini both 
comprising the globular domain which encompasses the ATP binding domain 
(106).  Although cohesin has been shown to be large enough to encompass both 
sister chromatids, as depicted in figure 2.1, an alternate hypothesis suggests that 
each cohesin ring encircles only a single sister, and that it is actually the two 
rings which intertwine to keep the strands together (see small insert 2.1) (191).  
           The exact mechanism of establishment of cohesion and the complete role 
of the cohesin complex have yet to be fully elucidated.  Several models exist for 
the deposition of cohesin onto DNA and for its transmission to newly replicated 
chromatin (reviewed (152)).  It was originally postulated that cohesion was 
established during replication (168).  In mammalian cells, cohesin has been 
shown to bind DNA as early as telophase in preparation for the next round of 
replication where the proteins Scc2 and Scc4 are required for loading of the 
cohesin complex (23).  Loading may occur in a step-wise manner (151) or by the 
addition of pre-formed complexes directly onto the DNA followed by DNA 
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replication through the center of the cohesin ring (23, 98).  However, it has also 
been shown that the fully formed cohesin complex exists free of chromatin and 
can associate with DNA without a requirement for replication (168). 
New evidence in a mammalian system suggests that cohesin binds to 
DNA dynamically beginning in telophase through G1, becomes stably bound 
throughout S phase peaking at the onset of G2, and the amount stably bound 
decreases again through prometa-metaphase to be dissociated at anaphase 
(46).  This would reinforce the theory that actual establishment of cohesion 
through the cohesin complex requires S phase replication of DNA, still allowing 
for the association of the cohesin complex and accomplishment of tasks not 
related to cohesion throughout interphase through transient binding. 
The Scc1/Smc1/Smc3 complex has been shown to be recruited to sites of 
DNA damage and to insulator regions of both cellular and viral DNA.  The 
cohesin complex is recruited to the site of double strand breaks (DSB) in 
mammalian cells by the Smc5 and Smc6 proteins (132).   Once localized to the 
site Smc1/3 are phosphorylated by the kinases ATM (ataxia telangiectasia 
mutated) and ATR (78, 189).  The exact role of cohesin in DSB repair is not 
known.  It has been shown, however, that in response to DNA damage cohesin 
can be loaded independent of DNA replication (160, 169).   
The cohesin complex has been demonstrated to be localized to CCCTC-
binding factor (CTCF) sites on human chromosomes, indicating a role for cohesin 
as a transcriptional insulator.   Cohesin is directed to consensus binding sites by 
the insulator protein CTCF, however the insulator activity of the complex requires 
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the presence of cohesin, possibly without the establishment of cohesion (177).  
Cohesin has also been reported to associate with CTCF on lytic control regions 
of Kaposi’s sarcoma herpes virus (KSHV) to repress their transcription, and loss 
of CTCF leads to episomal instability in cell culture systems (155).   
              Cohesin is removed from chromatin through two mechanisms (98, 174).  
The majority is released from the chromatid arms by a cleavage-independent 
mechanism during prophase.  The remaining cohesin, localized to the 
centromeres, is removed by the degradation of securin by APC/C at metaphase, 
resulting in the release of separin which cleaves Scc1 at anaphase onset (see 
Figure 2.2).  
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Figure 2.2    Cohesin in the Cell Cycle. 
A timeline of the removal of cohesin from sister chromatids 
          during mitosis.  Waizenegger 2000 (174). 
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ChlR1 
 
hChlR1 is the human homologue of the yeast helicase, CHL1 (5).  In 
budding yeast CHL1 was shown to be required for sister chromatid cohesion 
(150).   Knockout of ChL1 in yeast results in a mis-segregation phenotype 
characterized by loss of specific chromosomes and chromosome non-disjunction 
(47).     Work with mammalian ChlR1 has shown that a homozygous knockout in 
mice is embryonic lethal, with a high percentage of the cells displaying 
aneuploidy, a decrease in chromosomal cohesion and an increase in mis-
segregation (73).  Work in this lab has shown that knockdown of hChlR1 leads to 
lack of cohesion in cell culture resulting in a prolonged mitosis, with cells stalled 
at pro-metaphase, and eventual mitotic failure (124).     Parish, et al also showed 
that ChlR1 can be found in complex with the cohesion proteins Smc1, Smc3 and 
Scc1.   
ChlR1 was of interest to this lab as it was identified as an E2 binding 
partner in yeast two-hybrid assays, in work originated by Regina Park.  Additional 
work by J.L. Parish has shown that E2 and ChlR1 co-localize in interphase cells 
and through prophase in mitotic cells.  A point mutation in the transactivation 
domain of E2 (W130R) was able to abrogate E2 binding to hChlR1 and resulted 
in loss of E2 from mitotic chromatin in transfected cell lines.  Knockdown of 
ChlR1 using siRNA also resulted in dissociation of E2 from cellular chromatin.  
Interestingly this point mutation did not affect binding of E2 to Brd4, nor did 
knockdown of this Brd4 result in loss of E2 association with mitotic chromatin.  
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Taken together this showed that ChlR1 is required for mitotic segregation of E2 
(123). 
This led to the question, since ChlR1 binds to cohesin and is required for 
mitotic segregation of chromosomes, is there a role for the cohesin proteins in 
partitioning of the papillomavirus genome? 
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Materials and Methods 
 
Cell Culture.  Scc1 myc HeLa cells were a generous gift from J.M. Peters.  
pMEP CV-1 FLAG HPV11 E2 and FLAG HPV16 E2 were a generous gift from A. 
McBride.  hScc1 was cloned into the pTRE2 inducible vector system.  Scc1-myc 
HeLa cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(Invitrogen, Carlsbad CA.) with 10% fetal calf serum (Atlas Biologicals, Fort 
Collins CO), Pen/strep 100U/ml (Invitrogen), G418 200 µg/ml, hygromycin 200 
µg/ml.  Expression of hScc1-myc was induced by the addition of doxycycline to a 
final concentration of 2 µg/ml for 48 hours at 37 ºC (64).    ID13 and pMEP CV-1 
cells were cultured at 37 C in Dulbecco’s Modified Eagle Medium (Gibco) with 
10% fetal bovine serum, penicillin/streptomycin (100 U/ml) in 5% CO2.  1.4 X 10
6 
ID13 cells were plated in a 10 cm dish and 24 hours later were synchronized 
using 5 mM thymidine (Sigma) for 12 to 16 hours (G1/S) or 100 ng/ml 
nocodazole for 12 hours (M).  pMEP cells were induced to express E2 by the 
addition of 1 µM CdSO4 for 4.5 hours.  hTERT-RPE1 cells were cultured in 
DMEM/F12 medium containing 10% fetal bovine serum, and 100 units/ml 
penicillin and 100 g/ml streptomycin. 
 
Immunoblot and Immunoprecipitation.  Cells (2x106/10 cm dish) were rinsed 
two times with sterile PBS and then with 1 ml cold PBS containing 1 mM 
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dithiothreitol (DTT), and 1 mM PMSF was added to each plate.  Cells were 
scraped into a 1.5 ml tube and centrifuged at room temperature 1000g for 3 
minutes.  Supernatant was removed, and pellets were used immediately or 
frozen at -80 ºC for up to one week.  Frozen cells were thawed on ice for 20 
minutes, the lysed in 200 µl lysis buffer (50 mM Tris-HCl [pH 8.0] 100 mM NaCl, 
20 mM NaF, 10 mM KH2PO4, 0.1 mM DTT, 1% Triton X-100, 10% glycerol, 
Roche complete protease inhibitors, 1mM PMSF), incubated on ice for 30 
minutes then centrifuged at 13000 g for 10 minutes at 4ºC to pellet debris.  
Samples requiring DNAse digestion were treated with 0.02 U/µl RQ1 DNAse 
(Promega) for 30 minutes at room temperature.  Protein concentration was then 
determined using BCA assay (Pierce).  For Immunoblot (western), 20 µg protein 
was loaded into each well of an SDS poly-acrylamide gel (E2 10%; hScc1 8%; 
together 10%).  For immunoprecipitation equal amounts of protein in lysis buffer 
were added to binding buffer (50 mM Tris-HCl [pH8.0], 100 mM KCl, 0.1 mM 
EDTA, 0.2% NP-40, 0.1% BSA, 2.5% glycerol, 2 mM DTT, 1mM PMSF, protease 
inhibitors) at a 1:1 ratio along with 10 µl protein A Sepharose beads (rabbit II-1), 
or 10 µl protein G Sepharose beads (9E10 Ab or B201/B202).  
Immunoprecipitate 2 hours, 4ºC with agitation.  Immunoprecipitation was followed 
by three washes with washing buffer (100 mM Tris-HCl [pH 8.0], 100 mM NaCl, 
0.5% NP-40, 2 mM DTT, 1 mM PMSF) at room temperature.  Supernatant was 
removed and samples boiled in 20 µl 2X SDS-PAGE loading buffer (62.5 mM 
Tris [pH 6.8], 10% glycerol, 2% SDS, 1% DTT, 0.02% bromophenol blue, 12.5 
mM EDTA) and loaded onto a polyacrylamide gel.  Following gel electrophoresis 
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samples were transferred onto PVDF membrane (Pall) at 23v for 1 hour.  
Membranes were blocked overnight in 5% milk, TBST at 4ºC.  Primary antibody 
was incubated for 1 hour at room temperature with rocking (hScc1 is Rad21 
Abcam AB992 1:2500, II-1 1:2500, B201/02 supernatant 1:50).    Anti-rabbit HRP 
or anti-mouse secondary was diluted 1:10000 in 1% milk/TBS-T and incubated 
with the blot for 1 hour.  This was followed by extensive washing with TBS-T and 
all blots were developed with Thermo (Pierce) SuperSignal West Dura 
fluorescence detection kit. 
 
Chromatin immunoprecipitation (ChIP).  ChIP was performed using a protocol 
modified from Upstate Cell signaling.  HeLa and C33a cells were cross-linked by 
the addition of formaldehyde (Sigma) (final concentration of 1%) to cell culture 
media.  Cells were incubated for 10 minutes at 37ºC, and washed with cold 
phosphate buffered saline (PBS), and scraped into a 1.5 ml collection tube. 
Nocodazole synchronized cells were collected using mitotic shake-off washed 
with cold PBS and centrifuged at 1000 g.  Cells were resuspended in 250 l lysis 
buffer (1% sodium dodecyl sulfate (SDS), 10mM EDTA and 50 mM Tris-HCl, pH 
8.1) and incubated on ice for 10 minutes.  Lysates were sonicated for 50 seconds 
in 10-second pulses at 30% output (Fisher Scientific dismembrator), then 
centrifuged at 14000 g for 10 minutes at 4 C. The supernatant was then removed 
and diluted 10 fold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 
mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl,  1 mM PMSF, Roche 
complete protease inhibitor).  The ChIP lysate was pre-cleared by the addition of 
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30 l protein A agarose bead slurry (protein G for mouse monoclonals) (Upstate 
Cell Signaling) and incubation at 4 C, with agitation, for a minimum of 1 hour.  
After centrifugation the supernatant was removed and added to 50 l fresh beads 
containing 5 l II-1 rabbit anti-E2 antibody, 5 l rabbit pre-immune serum, 3 l 
9E10 Ab (Santa Cruz ), or 20 l monoclonal B202 supernatant. Following 
overnight incubation at 4 C beads were pelleted at 4000 rpm and washed with 
cold low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris 
HCl, pH 8.1, 150 mM NaCl), high salt wash buffer (0.1% SDS, 1% Triton X-100, 
2 mM EDTA, 20 mM Tris HCl, pH 8.1,  500 mM NaCl),  LiCl wash buffer (0.25 M 
LiCl,  1% NP40, 1% deoxycholate,  1 mM EDTA,  10 mM Tris HCl, pH 8.1), and  
twice with cold TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).  Complexes 
were then released from the beads using one-15 minute incubation with 100 l 
elution buffer (1% SDS, 0.1M NaHCO3).   The eluates were reverse crosslinked 
by incubation with NaCl (final concentration of 0.2M) at 65 C for 4 hours.  
Samples then were digested with 20 g proteinase K (Invitrogen) at 45 C for 1 
hour with the addition of EDTA to 0.01M and Tris HCl, pH 6.5, to 0.04 M.  DNA 
was recovered using QIAquick PCR purification kit (Qiagen).  DNA was re-
suspended in water and analyzed by PCR.   
 
In vitro binding assays (contributed by J.L. Parish) 
GST E2TAD, E2R and GST were expressed and purified as described by Yao, et 
al.  (188). Smc1, Smc3, Scc1 cDNAs were amplified from a HeLa cDNA library 
and cloned into pcDNA3. Proteins were in vitro translated using either rabbit 
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reticulocyte lysate or wheat germ extract TNT kit (Promega) in the presence of 
35S-methionine (Perkin Elmer). For removal of DNA, samples were treated with 
0.02 U/ l DNase RQ1 (Promega) for 20 minutes at 37ºC. 2 g of purified GST or 
GST-E2 proteins bound to 20 l of 50% glutathione Sepharose slurry were 
incubated with 10 l radiolabeled proteins in binding buffer (100 mM Tris-HCl [pH 
7.9], 150 mM NaCl, 0.1% NP-40, 1 mM DTT, 0.02% BSA) for 90 minutes at room 
temperature with agitation. Beads were washed three times (100 mM Tris-HCl 
[pH 7.9], 150 mM NaCl, 0.1% NP-40, 1 mM DTT), separated by SDS-PAGE and 
quantified using a PhosphorImager (Fuji) and ImageQuant software.   
 
Antibodies.  II-1 Ab used 3 µL for co-IP; B201/B202 20 µl supernatant; 9E10 1µl 
(Santa Cruz SC-40 );  Scc1 (Abcam Ab 992) 1 µl IP, 2 or 3µl ChIP. Anti-FLAG Ab 
was obtained from Sigma (monoclonal M2 F-3165).   
 
PCR.  Primers for the BPV LCR are 5’-aaagtttccattgcgtctgg-3’ sense, 5’- 
gctttttctagttagctggctatttt-3’ antisense, with an annealing temp of 54ºC.  The 
average number of cycles required was 25. 
pBABE-puro primers  are 5’-gtcaccgagctgcaagaact-3’ sense and  
5’-caggaggccttccatctgt-3’ anti-sense. 
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Results 
 E2 and ChlR1 were found to be binding partners, and ChlR1 was found to 
bind to members of the cohesin complex, this led us to examine cohesin proteins 
to see if they, in fact, bound to E2.  In work performed in this lab by Angela M. 
Bean, FLAG-HPV11 and FLAG-HPV16 E2 were induced in the pMEP cell line,  
co-immunoprecipitated using anti-Flag antibody, and immunoblotted for the 
cohesin protein Scc1 (Figure 2.3).   A small percentage of Scc1 clearly co-
immunoprecipitated with FLAG-E2 (2.3.A).  To examine whether the interaction 
was detectable within a system expressing physiological levels of E2, the co-IP 
was again performed on the ID13 murine cell line which stably maintains the 
BPV1 genome.  Scc1 clearly co-immunoprecipitated with endogenous E2 in ID13 
cells and not in the parental C127 cell line that does not express the BPV 
genome.  These results indicate that E2 binds to cohesin proteins in 
asynchronous cells when over-expressed and at lower endogenous levels. 
          To further explore the interaction between E2, hChlR1 and Scc1 the 
hScc1-myc HeLa cell line was obtained from the lab of J.M. Peters (64).  These 
cells express an Scc1 construct containing 9 myc-epitope tags at the C-terminus 
directed by a tetracycline inducible promoter.   Figure 2.4 illustrates detection of 
hScc1-myc in only the induced lanes.  Antibody to endogenous hScc1 detects a 
band in both the induced and un-induced cell lines, with an additional band 
appearing above hScc1 corresponding to a higher molecular weight myc-epitope 
tagged hScc1.  
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Figure 2.3.     E2 co-immunoprecipitates with Cohesin Proteins 
 
                  A. pMEP-CV-1 cells that express FLAG-HPV11 or HPV16 E2 were        
 induced or left un-induced and immunoprecipitated for FLAG 
 with the M2 antibody (Sigma) and probed for hScc1.  ChlR1 (un- 
 induced panel) antibody precipitates hScc1.   
 
B. hScc1 co-immunoprecipitates with endogenous BPV1 E2 in ID13 
cells but not the parental C127 cell line using the B201 antibody.  
All panels include 5% input.   
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E2 was transfected into hScc-myc HeLa cells to examine the interaction 
between E2 and hScc1-myc in this cell line in the absence of BPV1 genomic 
DNA. E2 co-immunoprecipitates the labeled hScc1 in transfected cells using two 
different antibodies to wild type BPV1 E2 (Figure 2.5).   It appears there are also 
Scc1 degradation products present that do not precipitate.  An additional 
background band is also present in both induced and un-induced cells (marked 
with an asterisk).  
The HeLa cell line was next used to examine the interaction between 
hScc1 and BPV1 E2. Wild type BPV1 E2 (500 ng), expressed from the CMV 
promoter in a pCDNA3 construct, was transfected into HeLa cells (10 cm dish) 
24 hours post-induction, along with the E2 repressor protein (E2R)(250 ng) and 
the E2 mutant that does not bind to ChlR1, E2 W130R (500 ng).  The cells were 
harvested 24 hours later and co-immunoprecipitation experiments were 
performed with both E2 rabbit II-1 and 9E10 mouse antibodies (See Figure 2.6).     
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Figure 2.4  Detection of hScc1-myc in HeLa cells. 
Following 48 hour induction hScc2-myc HeLa cells were lysed and 
Run on an 8% acrylamide gel.  The left side was probed with    
monoclonal 9E10 myc-antibody (1:2500), the right with polyclonal Ab 
to hScc1 (1:2500).   Both were incubated with their corresponding  
secondary antibody at a 1:10,000 dilution then developed with the 
Super Signal West Dura kit (Thermo/Pierce). 
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Figure 2.5.     Co-immunoprecipitation of E2 and HScc1-myc in HeLa cells. 
 hScc1-myc HeLa cells were induced to express myc-tagged 
 hScc1 and immunoprecipitations were performed using  
 antibodies to E2 (II-1 rabbit or B202 mouse) and myc (9E10). 
 For each antibody the cells were induced with doxycycline  
 2 µg/ml 48 hours or were left untreated.  The arrow indicates 
 the position of full length hScc1.  Immunobot was performed 
 using 9E10 antibody and developed with Thermo Pierce Super 
 Signal West Dura kit.  10% input is shown on right.  The asterisk 
 is an unidentified background band. 
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Co-immunoprecipitation of hScc1-myc with E2 and E2 with hScc1-myc both 
proved to be increasingly problematic.  E2, E2R and E2W130R were 
immunoprecipitated with hScc1-myc and the reverse IP worked as well (not 
shown).  The difficulties were primarily with the un-induced negative control cell 
lines.  In all cases the immunoprecipitation detected the target proteins 
regardless of whether the cells had been induced (See Figure 2.6).  This is 
possibly due to background expression which is visible, faintly, in the uninduced 
cells (See input panel below).  It is also possible that there are additional proteins 
in complex with E2 that might react with the 9E10 antibody, the primary 
alternative being C-Myc itself.  However, there was never a clear indication, in 
the form of a band in the 60-70 kDa range in a 9E10 blot, that C-Myc was 
present in the IP, aside from possibly the first IP with E2 (Figure 2.5 asterisk).  
Additional attempts were made to continue these experiments with the hScc1-
myc HeLa cell line.  The salt content of the wash buffer for immunoprecipitation 
was increased up to 500 mM, the beads were given an additional pre-block in 5% 
BSA or milk buffer, the amount of E2 was reduced to 500 ng/10 cm dish, and an 
additional DNAse digestion step was added prior to the immunoprecipitation in 
the event that all proteins were binding non-specifically to DNA.  None of these 
strategies were successful in blocking the binding in the un-induced cell lines.   
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Figure 2.6.  Co-immunoprecipitaion of E2 and hScc1-myc in transfected 
   HeLa cells. 
   Induced and un-induced HScc1-myc HeLa cells are transfected 
  with BPV1 E2, E2R or W130R immunoprecipitated with 9E10                                              
  antibody and blotted with anti-E2 II-1 (top panel). The arrow   
  indicates the position of full length E2.   The bottom panel depicts 
  5% input for both uninduced and induced cells.  E2 was detected   
  with the II-1 rabbit antibody. 
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 In addition to co-immunoprecipitation assays, ChIP assays were also 
undertaken on the hScc-1 myc HeLa cell line in order to determine whether the 
tagged cohesin protein would interact with the BPV1 genome.  Cells transfected 
with the BPV1 genome were induced at 24 hours post-transfection and then 
harvested for ChIP 48 hours later.  The ChIP data correlated with expected 
expression of the inducible hScc-myc (Figure 2.7).  However the BPV1 genome 
was detected in the un-induced HeLa cell line.  BPV1 E2 expression was 
sufficient in these samples for ChIP of the viral genome using the II-1 antibody 
(Figure 2.7 lower panel).   To determine whether the cohesin protein was binding 
to replicated DNA, a portion of the product of the ChIP assay was digested with 
DpnI.  There is a restriction site for this enzyme located between the primers of 
set C.   In Figure 2.8 the cohesin protein ChIPs the BPV1 genome without the 
DNA having replicated, as does BPV1 E2, evidenced by the lack of PCR product 
in DpnI digested samples.  Scc1 is loaded onto the viral DNA, and it interacts 
with E2, but it is not clear whether the hScc1-DNA interaction is dependent on 
E2.  To determine E2 dependence an empty vector and the BPV1 genome were 
transfected into the hScc-myc HeLa cells.  The cells were induced as previously 
described and harvested for ChIP assay.  
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Figure 2.7  ChIP of the BPV1 genome transfected into hScc1-myc HeLa   
         Cells. 
Cells were transfected with 150 ng BPV1 genome, induced to                            
express myc-tagged hScc1 24 hours post transfection and harvested 
                   48 hours later. Top panel hScc1 ChIP for the viral LCR.  Bottom  
panel is BPV1 E2 ChIP using  II-1 A.   Primer set C was used for 
PCR of all samples.   
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Figure 2.8  ChIP and digestion of BPV1 genome in hScc1-myc HeLa Cells. 
        hScc-myc HeLa cells were transfected with BPV1 genomic DNA and  
         24 hours later were induced to express hScc1 myc.  At 72 hours  
         post-transfection cells were harvested for ChIP assay.  Samples  
         were digested with DpnI or mock digested and PCR was run using 
         primer set C.  The top panel are results of ChIP with 9E10 for  
         hScc1-myc, the bottom for E2 using the II-1 antibody.  
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hScc1 was induced as in previous experiments and harvested at 72 hours.  The 
results are illustrated in figure 2.9.   In addition to the 9E10 antibody, a 
commercial antibody to hScc1 was used (Abcam anti-Rad21 Ab992).  PCR 
primers were designed for the pBABE-puro vector covering nucleotides (537-
743).  E2, hScc1-myc and hScc1 immunoprecipitated the BPV1 genomic DNA.  
Samples transfected with pBABE-puro only produced a PCR product in the 
presence of either the hScc1 antibody or the 9E10 monoclonal antibody.  This 
data, combined with data from previous figures indicates that hScc1 will bind to 
the papillomavirus genomic DNA that has not replicated, and that binding to 
plasmid DNA is not dependent on the presence of the papillomavirus E2 protein.  
 Chromatin immunoprecipitation data in the inducible HeLa cells was 
collected from an asynchronous population.  It is thought that cohesion is 
established in S-phase cells (168).  To  determine whether cohesion is 
established in the binding of cohesin to BPV genomic DNA, ChIP was performed 
in the mouse ID13 cell line synchronized by either the addition of 5 mM thymidine 
(G1/S) or 2 ng/ml nocodazole (M phase).  Asynchronous cells were also 
included.  Figure 2.10 is a graph of real-time PCR for primers in the LCR region 
showing E2 and hScc1 in both asynchronous and cycled cells.  E2 can 
immunoprecipitate the genome readily in all phases of the cell cycle, with the 
strongest bands appearing in the asynchronous cells.  ChIP of hScc1 appears to 
be cell cycle dependent with no binding in cells blocked at G1/S, some in 
asynchronous and the strongest binding occurring in cells blocked in early 
mitosis.  
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Figure 2.9  ChIP of E2, CTCF, hChlR1 and hScc1. 
ChIP performed on hScc1-myc HeLa cells transfected with either the  
BPV1 genome or pBABE-puro.   hScc1 antibody Abcam      (Ab992).  
Input is diluted 1:10 for PCR.     
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Figure 2.10  RT-PCR of ChIP samples. 
                     The BPV1 genome was immunoprecipitated with either the antibody  
                     to E2 (II-1 rabbit) or hScc1 (Ab992) in ID13 cells blocked at G1/S  
                    (Thy), mitosis (Noc),  or in asynchronous cells (Asyn).  The binding 
                     is calculated as percent of input, after subtraction of PB (negative 
                     control) from each sample following 45 cycles of RT-PCR (MJ  
                     Research).   
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Figure 2.11.  Immunoprecipitation of E2 and hScc1 in ID13 Cells. 
                      ID13 cells were synchronized with either 5 mM thymidine, 100  
                      ng/ml nocodazole or were left asynchronous.  Upon harvest lysates    
                      were immunoprecipitated with a mix of BPV1 monoclonal  
                      antibodies (B201/B202) and run on a 10% acrylamide gel,   
                      transferred to a PVDF membrane , and blotted for hScc1 using   
                      Ab992 (Abcam).  
 
 
                      Bottom panel courtesy of J.L.Parish.  C33a cells were  
                      untransfected (lane 1) transfected with BPV1 E2 (lane 2), 
                      E2 W130R (lane 3), or E2R (lane 4). 
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 Based on the results of the ChIP data in synchronized cells, another 
experiment was undertaken to determine cell cycle dependence of the E2/hScc1 
interaction.  ID13 cells were synchronized and the E2 protein was 
immunoprecipitated with the monoclonal antibody B201.  An immunoblot for 
hScc1 using the rabbit polyclonal antibody showed a co-IP of the cohesin protein 
only in asynchronous cells (Figure 2.11).   In order to determine whether this 
interaction was dependent on ChlR1, an E2 mutant that does not bind ChlR1 was 
transfected into C33a and immuoprecipitated with the E2 monoclonal antibody 
B202.  Both E2 and E2 W130R bind hScc1, suggesting that the interaction of E2 
with cohesion proteins is independent of ChlR1 (Figure 2.11 bottom panel). 
 Dr. Joanna Parish did additional in vitro work to establish the regions of E2 
that interact with the cohesin proteins.   Nucleotides 1-216 and 162-420 of BPV1 
E2 were generated as gst-fusion proteins and expressed in E. coli.  Figure 2.12.A 
shows coomassie stain of the purified proteins.  These mutants and gst 
expressed alone were mixed with [S35] labeled proteins and precipitated with 
glutathione-Sepharose beads.  The results are shown in figure 2.12.B. and 
quantified in 2.12.C.  Both the transactivation domain of E2 (1-216) and E2R 
(162-410) bind to three cohesin subunits, Smc1, Smc3 and Scc1.  Digestion with 
DNAse (figure 2.12.D., quantified in 2.12.E.) resulted in loss of the interaction 
between the cohesin proteins and E2R, indicating that the positive result here 
emanates from the interaction between these proteins and a DNA intermediary.  
An interaction does remain between the E2TAD and three proteins of the cohesin 
complex.  
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Figure 2.12  Mapped Binding of E2 with hScc1. 
  Courtesy of J.L. Parish.  Figure 2.12.A. coomassie staining of gst- 
  E2TAD (1-216), gst-E2R (162-410) and gst, purified from E. Coli.   
2.12.B. Purified E2 on gst-Sepharose beads combined with in vitro 
[S35]-methionine labeled cohesin proteins Smc1, Smc3 and Scc1 
and separated using SDS-PAGE.  Quantification (2.12.C) with 
ImageQuant software (Fuji) based on 10% input.    2.12.D.  In vitro 
translations were digested with DNAse and repeated as described 
above, with quantitation in 2.12.E.  hChlR1 used as a positive 
control for E2 binding, TnT luciferase as a negative. 
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 In an attempt to link hScc1 binding to the viral genome, and loading of 
cohesin by the ChlR1 protein, we analyzed the association of ChlR1 with the 
BPV1 episome in cycled ID13 cells.  Cells were synchronized as previously 
described, and ChIP assays were performed with the II-1 rabbit anti-E2 antibody, 
the hScc1 rabbit polyclonal, and a goat anti-ChlR1 antibody developed in this lab 
(124).   ChlR1 and E2 both bind to the viral genome during S phase (2.13.B. top 
panel).  E2 and hScc1 are localized to the LCR at the onset of mitosis, but not in 
G1/S phase.  The hScc1 data correlates with previous data obtained with hScc1 
and the BPV1 genome in cycling cells (Figure 2.10), and the ChlR1 data is 
consistent with published data regarding dissociation of the protein from E2  and 
cellular genomic DNA in mitosis (123).   In addition, hScc1 has been shown to 
co-localize with CTCF at regions of genomic and viral DNA.  Preliminary data 
shown here suggest that CTCF may also serve an insulator role in regulation of 
papillomavirus proteins, as the BPV genome immunoprecipitates with antibody to 
CTCF.   
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Figure 2.13.  ChIP of Cycled ID13 Cells. 
  A. ID13 cells are asynchronous (left panel), stalled at G1/S with  
       5 mM thymidine (center) or in mitosis with 100 ng/ml 
       nocodazole (right). 
 
  B. ChIP of ID13 cells at G/S (top panel) or Mitosis (lower panel). 
      Samples were immunoprecipitated with the II-1 E2 rabbit  
                antibody, hScc1 (Ab 992), a goat anti-ChlR1, rabbit anti-CTCF  
       (Bethyl Labs A300-543A) or pre-immune serum (PB).  
                          PCR primer set for the viral LCR 25 cycles. 
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Discussion 
 Previous work in this lab by Joanna Parish, et al has shown a requirement 
for ChlR1 in eukaryotic cells.  The helicase is required for cohesion of sister 
chromatids and interacts with the cohesin proteins Scc1, Smc1, and Smc3  
(124).  Dr. Parish also demonstrated that ChlR1 is required for proper 
segregation of the papillomavirus genome in replicating cells. This was 
accomplished by  the creation of a mutation in BPV1 E2 that abrogates the 
interaction between E2 and ChlR1, resulting in a loss of viral genomes in a stable 
genome maintenance assay (123).  This posed the interesting question of 
whether the cohesin proteins are also required for long term maintenance of the 
papillomavirus genome in dividing cells.  The facts shown here support, but do 
not prove, that the mechanism required for stable propagation of the BPV1 viral 
genome is tethering of the viral genome through cohesion, mediated by E2 and 
ChlR1. 
 Initial data prepared in this lab by Angela Bean was very positive, with 
hScc1 detectably interacting with E2 in an overexpression system.  Follow-up 
experiments with endogenous E2 suggested that Scc1 does interact with BPV1 
E2 in a system that stably replicates viral genomic DNA (Figure 2.3).   
 hScc1 is a protein that plays a vital role in sister chromatid cohesion, and  
thus perturbation of its expression in cell culture is not well tolerated.  In an 
attempt to express tagged hScc1, several different constructs were made that 
contained an N-terminal tag (HA or FLAG) under the expression of a CMV 
promoter.  None of these constructs were properly expressed in transfected cell 
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lines, although protein was seen in in vitro translations of the constructs (data not 
shown).  A generous gift of the hScc-myc HeLa cells from J.M. Peters enabled us 
to examine some of target interactions in this system.  Data acquired here, 
although not quantified, suggests that the amount of hScc1 expressed cannot 
exceed a threshold level, as stable expression from an exogenous source did not 
exceed endogenous expression (Figure 2.4 and data not shown). 
 The HeLa cell line was not ideal for use with co-immunoprecipitation and 
ChIP assays.  The cross-reactivity with c-Myc or leaky expression gave constant 
high background in these experiments.  Extensive immunoprecipitation assays 
revealed very slight evidence of leaky expression in immunoblots.  However co-
IPs were positive in both the induced and control cells, making any data retrieved 
subject to all possible interpretations.  Although leaky expression was a 
possibility, the levels of tagged hScc1 protein seemed very low, which should not 
result in binding of equal strength to that in the induced cell line (Figure 2.6 and 
additional data not shown).  As previously mentioned, techniques that should 
have decreased non-specific binding to either beads or antibody did not reduce 
background in this assay.  This would suggest that the background binding is 
specific, and the result of binding of the antibody to the expressed myc-tagged 
protein or to the c-Myc protein.  ChIP assay in BPV1 transfected cells (not 
shown) reveals c-Myc bound to the viral episome, possibly with E2 and or BPV1 
E6.  It has been shown that c-Myc increases replication of the SV-40 origin of 
replication in monkey cells, and can replace the function of Large-T antigen (67, 
82).  More recent work reveals that c-Myc interacts with the pre-RC and localizes 
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to origins of replication (35).  Work is presently underway to determine the 
relationship between c-Myc and the papillomavirus genome.   
 ChIP assays with the 9E10 antibody in figures 2.7, 2.8 and 2.9 may be 
interpreted together.  Data in 2.9 suggests that a possible feed back loop 
governs expression of endogenous hScc1.  In cells that are not induced to 
express hScc1-myc, both the 9E10 antibody and the endogenous anti-hScc1 
antibody detect the viral genome in a ChIP assay.  Upon induction, there is little 
or no detection of endogenous protein on the viral genome.  In order for this data 
to be meaningful, two conditions must be fulfilled.  The first condition is that the 
hScc1 promoter must be regulated by a feedback loop.  This is highly possible 
given that the cohesin complex is now being seen as a negative regulatory 
protein that can inhibit gene expression (155, 177).  Excessive hScc-myc 
produced as a result of induction may diminish the amount of hScc1 transcribed 
from the endogenous promoter.  The second condition is that the hScc1-myc tag 
interferes with access of the antibody to its epitope.  hScc1 binding to the BPV1 
genome is seen with anti-hScc1 in both figures 2.10 and 2.13, so this antibody is 
effective at ChIP of this protein on the viral genome.  In Figure 2.9 this antibody 
works only in cells in which the tagged hScc1 is not induced.  The hScc1 
antibody was raised to the extreme C-terminus of the protein and it is possible 
the 9 myc tags placed here deny access of antibody to this region.  If these two 
conditions are accepted, figure 2.9 can be interpreted to show that E2 and hScc1 
bind to the BPV1 genome, while hScc1 additionally precipitates the empty 
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pBABE-puro vector.  This would reveal that E2 is not required for hScc1 to 
interact with episomal DNA.   
  Figures 2.7 and 2.8 shed additional light on the requirements for hScc1 
binding to episomal DNA. BPV1 can be immunoprecipitated with hScc1-myc in 
the HeLa cells (see Figure 2.7).  This ChIP was digested with Dpn1 and the 
results subjected to PCR for the viral LCR, which contains a Dpn1 restriction site.  
Figure 2.8 illustrates that both E2 and hScc1 bind to transfected viral DNA that 
has not yet been replicated.  This would not be unexpected, as although 
cohesion is established during S phase, cohesin can bind interphase DNA 
without necessarily establishing cohesion (23, 98, 168).    
 If cohesion is established on the BPV1 genome, it would be assumed that 
cohesin would be detectable on the viral genome during S phase.  We examined 
cohesin on the viral genome of ID13 cells that stably maintain BPV and are 
stalled on the border of G1/S.  hScc1 did not immunoprecipitate the genomes at 
this stage (figure 2.10 top panel).  It did, however IP in both asynchronous and 
mitotic cells.  It is also unexpected that ChlR1 and hScc1 ChIP in different 
phases of the cell cycle.  The role of ChlR1 in the establishment of cohesion is 
still unclear.  However, since cohesion can also be established in interphase to 
assist with DNA repair, it is possible that this mechanism is the one used to 
deposit cohesin on the BPV genome.  We are currently working to ascertain the 
details of the mechanism involved, and whether the interphase interactions play 
a more significant role in genome tethering than originally thought. 
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 The mutant W130R also does not perform as we would expect.  If E2 
binds to ChlR1 and this association is required for loading of cohesin onto viral 
DNA, then we would expect that a mutant that does not interact with ChlR1 
would not interact with hScc1.  Nonetheless, E2 W130R was detected with Scc1 
in transfected C33a cells (figure 2.11).  This suggests that the interaction of E2 
with hScc1 does not require ChlR1.    
 The above mentioned data, along with the ChIP of CTCF with the viral 
genome (Figure 2.13) might also suggest an additional role for cohesin in the 
papillomavirus life cycle.   In addition to a possible role in tethering of the viral 
genome during mitosis, cohesin could be responsible for repressing viral gene 
expression.  Work in the lab is ongoing to determine whether predicted insulator 
sites in the pre-E5 and L1 coding sequence of BPV1 are valid targets of CTCF 
and cohesin, and whether they are functional insulator regions.   
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Conclusions 
 The bovine papillomavirus E2 protein was shown here to remain localized 
to the E2 consensus binding sequences in the viral LCR throughout the cell 
cycle.  Clustered E2 sites upstream of the viral origin maintain E2 during viral 
replication.  It does not appear that E2 binds in stages, i.e. the protein is not 
found solely on the origin during replication, following which it leaves the genome 
and then is found only on the MME during mitosis.  The BPV1 MME maintains E2 
even when these binding sites are not serving to assist in segregation of the viral 
genome, and while those sites appear to be constantly filled, sites outside the 
LCR seem to rarely draw E2 in monolayer culture.  E1 does not associate with 
E2 at consensus sequences away from the origin of replication, as it 
immunoprecipitates only with DNA in the immediate vicinity of the initiation site. 
 ChIP with restriction enzyme digest, RED-ChIP, is a particularly useful 
combination of techniques that assist in analyzing adjacent genomic regions that 
are conveniently separated by a restriction sequence.  It enabled the examination  
of distinct segments of a compact portion of the viral LCR which would not have 
been discernable using a standard ChIP assay.   
  E2 mediated genomic segregation of the BPV1 episome has been shown 
to require ChlR1.  Clarification of the mechanism through which this occurs 
implicates the cohesin protein complex.  Cohesin can be detected binding to E2 
through the TAD in asynchronous cell culture independently of ChlR1 and to the 
viral genome at the onset of mitosis.  ChlR1 and the cohesin complex 
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perceivably ChIP on the viral genome at different stages of the cell cycle.  
Cohesin binds to the genome without a requirement for E2, and can associate 
with viral and plasmid DNA that has not replicated.   
 The insulator protein CTCF binds the viral genome and ChIPs in cells 
blocked at G1/S, but has been removed from the DNA by early mitosis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
143 
 
 
 
Future Directions 
 Continued work is needed on the occupation of E2 recognition sequences 
in the viral genome.  Several of these are located outside the viral LCR, have 
extremely low affinity for E2 and have not been shown to be occupied by the 
protein.  It is important to know if E2 associates with these regions at any point in 
the viral life cycle, which can be mimicked in cell culture by differentiation of cell 
lines stably expressing the BPV1 genome.  A switch in the usage of these 
regions may be the result of, or initiate, high output viral DNA replication found in 
differentiated keratinocytes.  Use of re-ChIP might also be re-visited to determine 
whether E2 is actually present at the origin when E1 is present.   
 This work inadvertently led to intriguing questions regarding the role of c-
Myc in BPV1 replication.  Does Myc interact with E2, and if so does it have a role 
at the origin of replication, in the presence or absence of E1 and E2?  E6 and c-
Myc interact, as do E6 and E2.  Does E6 have a role in initiation of replication in 
vivo and what would that be?  Work on this project is now on-going in the lab.  
ChIP and co-immunoprecipitation experiments are being combined to answer 
these questions.  This lab has a large panel of mutants of both E2 and E6.  
These could help determine the functional relationships of these proteins with c-
Myc in the replication process.  
 Does papillomavirus subvert the replication licensing requirements of the 
cell, and if so how?  What cellular proteins are required to launch genome 
duplication in cell culture and which are not?  If not is there a viral gene that fills 
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the requirement for the cellular component or an additional method to avoid 
activation of cell cycle checkpoints?  We now have an increased ability to 
consider the option of mass spectrometry for identification of proteins.  This might 
be a viable alternative here to identifying each origin protein using antibodies and 
immunoblotting.   
 Both the cohesin complex and hScc1 bind to E2 and to the viral genome 
and may be involved in several facets of the viral life cycle.  The roles of these 
proteins in transcription, tethering and DNA repair need to be further evaluated.  
Identification of the mechanism behind the interaction between the viral genome 
and cohesin might lead to a more in depth understanding of cohesin and 
cohesion in the mammalian system.  This includes the establishment of cohesion 
versus the binding of cohesin and the role of ChlR1 in loading of the cohesin 
complex.  Both replication dependent and independent methods might factor into 
the viral life cycle.   E2 is required for proper distribution of the viral genome to 
sister chromatids.  How does it regulate cohesin deposition and interaction with 
hChlR1? 
 The CTCF protein interacts with hScc1 and the BPV1 genome.  Is it 
localized to the putative insulator sequences determined by the computer 
algorithm (insulatordb.utmem.edu)?  Do the proteins co-localize to these 
sequences?  Does removal/disruption of these sequences affect expression of 
early or late viral genes, and are these sites regulated in monolayer and 
differentiated cell culture?  Many of these questions are currently under 
investigation in the Androphy lab. 
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